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ABSTRACT
The main focus of this research was to evaluate the ability of a novel
multifunctional nanoparticle to mediate drug delivery and enable a non-invasive approach
to measure drug release kinetics in situ for the treatment of cancer. These goals were
approached by developing a nanoparticle consisting of an inorganic core (i.e. gadolinium
sulfoxide doped with europium ions or carbon nanotubes). This was coated with an
external amphiphilic polymer shell comprised of a biodegradable polyester (i.e.
poly(lactide) or poly(glycolide)), and poly(ethylene glycol) block copolymer. In this
system, the inorganic core mediates the imaging aspect, the relatively hydrophobic
polyester encapsulates hydrophobic anti-cancer drugs, and poly(ethylene glycol)
stabilizes the nanoparticle in an aqueous environment.
The synthesis of this nanoparticle drug delivery system utilized a simple one-pot
room temperature ring-opening polymerization that neglected the use of potentially toxic
catalysts and reduced the number of washing steps. This functionalization approach could
be applied across a number of inorganic nanoparticle platforms. Coating inorganic
nanoparticles with biodegradable polymer was shown to decrease in vitro and in vivo
toxicity. Nanoparticles could be further coated with multiple polymer layers to better
control drug release characteristics. Finally, loading polymer coated radioluminescent
nanoparticles with photoactive drugs enabled a mechanism for measuring drug
concentration in situ. The work presented here represents a step forward to developing
theranostic nanoparticles that can improve the treatment of cancer.

ii

DEDICATION
This work is dedicated to my family: Mom, Dad, Matthew, and David. Thank you
for all the years of support and love.

iii

ACKNOWLEDGMENTS
I would like to acknowledge my advisor Dr. Frank Alexis for his guidance and
patience through this journey. Thank you for always pushing me to achieve beyond the
required, and to learn as much as possible. Thank you to my committee members for your
input at each critical stage of this process. Thank you to the faculty and staff in the
Department of Bioengineering at Clemson University, which has served as my home for
the past eight years. Much thanks to my many collaborators: Dr. Rao and Dr. Podila
(Department of Physics at Clemson University), Dr. Whitehead and Dr. Anker
(Department of Chemistry at Clemson University), Dr. Brown (Department of
Pharmacology and Toxicology at East Carolina University), Dr. Van Horn (Department
of Chemistry and Biochemistry at the College of Charleston), and Dr. Globus (Bone and
Signaling Laboratory at the NASA Ames Research Center). All of your guidance,
experience, and wisdom has proven invaluable. A special thanks to Dr. Guzeliya
Korneva, Dr. Terri Bruce, Linda Jenkins, and Kim Ivey for all forms of technical
guidance. Thank you to Maria Torres for always tempering my anxiety.
To my family, thank you for your support: Mom, Dad, Matthew, and David, I
could not have completed this without you. I love you all. Thank you to the
Nanomedicine lab members past and present, especially the undergraduates whom have
helped me along the way. A special thanks to Brandon Mattix! Thank you to all of my
friends for allowing me to disappear for months on end. A special thanks to Kevin
Dejonckheere, Dan Wagoner, Eric Owensby, Andrew Boddiford, and Cameron Bell.
Prost!

iv

TABLE OF CONTENTS

Page
TITLE PAGE .................................................................................................................... i
ABSTRACT..................................................................................................................... ii
DEDICATION ................................................................................................................iii
ACKNOWLEDGMENTS .............................................................................................. iv
LIST OF TABLES ........................................................................................................viii
LIST OF FIGURES ........................................................................................................ ix
CHAPTER
I.

INTRODUCTION ......................................................................................... 1
1.1. Tumor Physiology and Challenges in Modern Chemotherapy ......... 2
1.2. Nanomedicine ................................................................................... 5
1.3. Theranostic Nanomedicine: Imaging Drug Delivery ........................ 9
1.3.1. Magnetic Resonance Imaging of Drug Release ................... 12
1.3.2. Optical Approaches to Measuring Drug Release ................. 14
1.4. Challenges in Theranostic Nanomedicine ...................................... 29
1.4.1. Factors Affecting Nanoparticle Toxicity .............................. 30
1.4.2. Optical Challenges in Theranostic Nanomedicine ............... 33
1.5. Conclusions ..................................................................................... 35
1.6. References ....................................................................................... 36

II.

MULTIFUNCTIONAL NANOPARTICLES TO IMPROVE THE SAFETY
OF DRUG DELIVERY ......................................................................... 49
2.1. Methods to Coat Inorganic Nanoparticles ...................................... 49
2.2. Results and Discussion ................................................................... 60
2.2.1. Preparation and Characterization of Coated NP................... 60
2.2.2. In Vitro Uptake, Toxicity, Inflammatory Response and
Controlled Release ......................................................... 64
2.2.3. In Vivo Biodistribution in Mice ........................................... 70
2.2.4. In Vivo Inflammatory Response and Toxicity ..................... 73
2.3. Conclusions ..................................................................................... 77

v

Table of Contents (Continued)

Page

2.4. References ....................................................................................... 78
III.

MULTILAYERED POLYMER COATINGS TO CONTROL
DRUG DELIVERY ............................................................................... 82
3.1. Principles of Controlled Drug Release ........................................... 82
3.2. Methods for Multilayered Coatings to Control Drug Release ........ 83
3.3. Results and Discussion ................................................................... 88
3.3.1. Preparation and Characterization of Multilayered
Carbon Nanotubes.......................................................... 88
3.3.2. Multilayered Nanoparticle Release Kinetics ........................ 91
3.3.3. In Vitro Efficacy of Drug-loaded Multilayered Particles ..... 92
3.4. Conclusions ..................................................................................... 94
3.5. References ....................................................................................... 96

IV.

RADIOLUMINESCENT NANOPARTICLES FOR IMAGING DRUG
DELIVERY.......................................................................................... 100
4.1. Quantitative Approaches to Measuring Drug Release .................. 100
4.2. Methods for Theranostic Radioluminescent Nanoparticles .......... 102
4.3. Results and Discussion ................................................................. 110
4.3.1. Preparation and Characterization of Polymer Coated
Radioluminescent Particles .......................................... 110
4.3.2. Quantifying Drug Loading in Coated Nanoparticles ......... 112
4.3.3. Kinetic PpIX Release Measurements ................................. 114
4.3.4. Cellular Uptake of Coated Nanoparticles ........................... 116
4.3.5. Ex Vivo Imaging in Porcine Liver and Biodistribution
in a Xenograft Model ................................................... 116
4.3.6. In Vitro and In Vivo Toxicity............................................. 119
4.4. Conclusions ................................................................................... 120
4.5. References ..................................................................................... 122

V.

CONCLUSIONS ....................................................................................... 125
5.1. Polymer Coatings Improve Nanoparticle Toxicity Profile ........... 126
5.2. Controlling Drug Delivery ............................................................ 128
5.3. Measuring In Situ Drug Concentration ......................................... 130
5.4. Limitations .................................................................................... 131
5.4. Summary ....................................................................................... 133

VI.

RECOMMENDATIONS ........................................................................... 134

vi

Table of Contents (Continued)
VII.

Page

LIST OF PUBLICATIONS ....................................................................... 142

vii

LIST OF TABLES
Table

Page

1.1

Summary of the methods for measuring the release of drug from
particles .................................................................................................. 11

2.1

Experimental plans to test the effect of polymer coating on toxicity
and drug delivery ................................................................................... 51

3.1

Experimental plans for multilayered nanoparticles. .................................... 85

4.1

Experimental plans for radioluminescent theranostic nanoparticles ......... 103

viii

LIST OF FIGURES
Figure

Page

1.1

Prognosis for the most deadly cancers remains poor,
especially when diagnosed at later stages ................................................ 1

1.2

Theranostic nanomedicine with real-time monitoring of
drug biodistribution, in situ concentration, and therapeutic
efficacy .................................................................................................. 10

1.3

Thermal sensitive liposomes are destabilized when
temperature is increased ......................................................................... 12

1.4

Temperature sensitive liposomes also encapsulated the
imaging agent Gd-DTPA and anticancer drug
doxorubicin. ........................................................................................... 13

1.5

Porous silicon (PSi) particles can be loaded with
daunorubicin via covalent conjugation .................................................. 16

1.6

pH-sensitive PBA-PEG nanoparticles are loaded with the
photoactive drug protoporphyrin IX (PpIX) .......................................... 19

1.7

Bi-fluorescence resonance energy transfer enables the
measure of drug loading onto quantum dot-aptamer
conjugates .............................................................................................. 21

1.8

Nanoparticle visible light luminescence, which may be
excited by NIR light, is attenuated by loaded drug ................................ 23

1.9

Radioluminescent Gd2O2S nanoparticles doped with
terbium and europium (Gd2O2S:Tb/Eu) were coated
with poly(styrenesulfonate sodium) and
poly(allyl-amine HCl) ............................................................................ 27

2.1

Chemical characterization of coated CNTs ................................................. 63

2.2

Chemical characterization of coated nGr ..................................................... 64

2.3

In vitro studies illustrate the uptake, toxicity, and
inflammatory response of CNT-PLA-PEG............................................ 67

ix

List of Figures (Continued)
Figure

Page

2.4

Live/Dead assay of nGr in U-138 cells ........................................................ 68

2.5

Controlled release of paclitaxel and in vitro therapeutic efficacy ............... 69

2.6

CNT-PLA-PEG biodistribution ................................................................... 71

2.7

Histology of CNT-PLA-PEG biodistribution .............................................. 72

2.8

Biodistribution of CNT-PLA-PEG and nGr-PLA-PEG in
U-138 tumor xenograft mice .................................................................. 74

2.9

In vivo inflammatory response and toxicity ................................................ 76

3.1

Schematic for the approach to coat multiple polymer
layers on CNT ........................................................................................ 84

3.2

Thermogravimetric analysis of single layer CNT ........................................ 89

3.3

Thermogravimetric analysis of multilayered CNT ...................................... 90

3.4

Transmission electron microscopy of multilayered CNT ............................ 91

3.5

Varying polymer coating thickness on CNT ............................................... 92

3.6

Dasatinib release from multilayered CNT ................................................... 93

3.7

In vitro therapeutic efficacy of dasatinib loaded
multilayered CNT .................................................................................. 94

4.1

Characterization of radioluminescent nanoparticles .................................. 111

4.2

Quenching radioluminescent nanoparticle with drug ................................ 113

4.3

Measuring drug release kinetics................................................................. 114

4.4

In vitro uptake of radioluminescent nanoparticles ..................................... 115

4.5

Radioluminescent imaging in ex vivo porcine tissue ................................ 117

x

List of Figures (Continued)
Figure

Page

4.6

Biodistribution of radioluminescent nanoparticles
in intracranial tumor xenograft models ................................................ 118

4.7

In vitro and in vivo toxicity of radioluminescent nanoparticles ................ 120

5.1

One-pot room coating of inorganic nanoparticle templates ....................... 126

5.2

Polymer coating decreases toxicity ............................................................ 128

5.3

Multilayer polymer coatings control drug release ..................................... 129

5.4

Theranostic nanoparticles can measure drug release ................................. 132

xi

CHAPTER ONE
INTRODUCTION
Although nanoparticle controlled drug delivery systems have significantly
increased the clinical efficacy of chemotherapeutic drugs [1], cancer remains the second
leading cause of mortality in the United States [2, 3]. Chemotherapy fails in part due to:
(1) diagnosis of disease at a late, aggressive, and metastatic stage (Figure 1.1), (2)
physiological barriers to drug delivery such as poor drug pharmacokinetics, poor tumor
penetration, development of multidrug resistance, and genetically different cancer cell
populations in tumors [4-7], and (3) effective methods for non-invasively determining
drug dose at the tumor site [8]. Although the fundamental understanding of cancer
biology is growing, diagnostic tools are becoming more advanced, and novel therapies
are becoming more effective; the World Health Organization projects that global cancer
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Figure 1.1 Prognosis for the most deadly cancers remains poor, especially when
diagnosed at later stages. Therefore development of more effective diagnostic and
therapeutic is expected to improve patient outcome.
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Nanoparticles are one platform with potential to improve both cancer diagnostics
and therapy. The National Nanotechnology Initiative (NNI) defines nanotechnology as
the research and utilization of materials on the size of 1-100 nm, however a broader
definition applies this label to technologies on the 1-1000 nm scale [9, 10].
Nanotechnology has been shown clinically to improve the delivery of drugs to solid
tumors [1, 11]. Furthermore, nanoparticles have been shown both in the lab and clinically
to have applications for cancer imaging [12]. In order to completely dissect challenges in
modern oncology, especially in the context of nanoparticle-mediated drug delivery and
imaging, a robust understanding of tumor physiology and specific challenges in drug
delivery is required.

1.1. Tumor Physiology and Challenges in Modern Chemotherapy
Understanding the anatomy and physiology of solid tumors is pertinent for
framing nanoparticle design parameters to optimize therapeutic efficiency. Nanoparticles,
due to their unique physical and chemical properties, are able to mediate both drug
delivery and imaging [1, 8, 9, 11]. Moreover, nanoparticles are able to overcome
physiological, cellular, and intracellular barriers to drug delivery. The structural
anomalies of solid tumors and aberrations in cellular markers allow clinicians and
researchers to actively or passively target cancer cells. Active targeting employs tumorspecific ligand binding to localize nanoparticle at the tumor site, whereas passive
targeting takes advantage of natural anomalies in tumors to increase localization at the
tumor site. During tumor growth, blood vessel development is irregular and the vascular
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network within tumors is heterogeneous [13-15]. Tumor vasculature is irregularly spaced,
exhibits ill-defined branching hierarchy [16], and is fairly tortuous [10]. Vessel dilation
and tortuosity causes a decrease in blood flow rate within the tumor. An increase in tumor
vasculature permeability is caused by widened intercellular defects and the lack of a
regular basement membrane [16]. Tumor vasculature is highly fenestrated with pores
between 400 and 600 nm [17, 18], and these fenestrated vessels allow small molecules
and nanoparticles to cross the endothelial layer. Maeda first described extravasation and
retention of small molecules and nanoparticles in tumors in 1986 as the enhanced
permeability and retention (EPR) effect [19, 20]. This phenomenon is generally restricted
to molecules with diameter <400-600 nm. The EPR effect has been employed as a
mechanism to passively target nanoparticles to tumors due to the extravasation and
retention within the tumor. The EPR effect is further enhanced by the lack of lymphatic
vessel development near tumors. However, reduced lymphatic drainage coupled with
fluid extravasation leads to high interstitial fluid pressure (IFP) within tumors. Tissues
with normal vascular architecture and healthy lymphatic drainage generally have an
interstitial fluid pressure of approximately 0 mm Hg, whereas tumor tissue will have an
IFP ranging from 7 to 60 mm Hg [16, 21]. The high IFP within tumors creates a
hydrostatic barrier to the delivery of drugs or nanoparticles into the tumor center.
Nanoparticles may overcome this hydrostatic barrier either through active targeting [22]
or via modification of nanoparticle physical properties (i.e. size and shape) [23-26].
Given that diffusion across the endothelial layer occurs, drug molecules or
nanoparticles must then navigate the dense tumor extracellular matrix (ECM). Tumor
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microenvironment, specifically the ECM, serves as a physical barrier to the diffusion and
convection of nanoparticles or drugs to the tumor center. Studies have shown that
collagen acts as a barrier to transport into tissue [26, 27], and Gullino, et al. [28] showed
that collagen content in eleven hepatomas in rats was between 1.2 and 6.4 times higher
than in healthy liver tissue. Nanoparticles must penetrate the dense ECM of solid tumors
in order to deliver their therapeutic payload to cancer cells. Nanoparticle size and surface
properties will influence the ability to navigate through the ECM. Krol et al. [29]
investigated the available volume fraction (KAV), the interstitial space that can physically
contain a therapeutic agent, by measuring the diffusion of fluorescently labeled inulin,
bovine serum albumin (BSA), and dextran in ex vivo fibrosarcoma ECM and model
ECM gels. The molecular weight cut-off (MWCO) was found to be roughly >40,000 Da.
More recently, Perrault et al. [30] showed in vivo that the diffusion of gold nanoparticles
was directly related to degree of PEGylation and inversely related to nanoparticle size.
Lieleg et al. [31] assert that nanoparticle size did not control the diffusion through the
ECM, rather electrostatic interactions between ECM components and the nanoparticle
surface charge determine diffusivity. Studies in ECM hydrogels show that ~1000 nm
polystyrene particles with cationic amine, neutral PEG, and anionic carboxyl coatings
exhibited similar behavior to ~170 nm liposomal formulations with corresponding
surface charges. Negatively charged carboxyl and positively charged amine liposomes
and polystyrene particles were relatively immobile in ECM gels, whereas the neutral
particles diffused freely. Thus it appears that nanoparticle diffusion through solid tumors
may be mediated by size, shape, and surface properties.
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Decreased intratumoral pH can act to reduce drug efficacy and cellular uptake
[32, 33]. As stated previously, tumor vasculature development is heterogeneous and
irregular. Thus, cells often grow at distances far enough from capillaries such that oxygen
and nutrient diffusion is insufficient [34, 35]. The diffusion limit of oxygen in a model
tissue cylinder is between 100-200 µm [36], and tumor cells growing beyond 180 µm
from blood vessels were observed to undergo necrosis due to insufficient nourishment
[16, 35]. Oxygen-deprived cancer cells may become chronically hypoxic and undergo
phenotypic mutations, inducing aggressively growing cancer cells. Chronic hypoxia also
results in changes to cellular metabolism, resulting in an acidic microenvironment. Thus,
nanoparticles must shield therapeutic agents from acidic environment and improve
delivery into the cell. If the primary cancer is not completely eliminated, cancer cells may
develop resistance to therapeutic agents. Thus, the most effective theranostic agents will
be able to navigate all of the physical and chemical barriers associated with solid tumors,
and completely eradicate all cancerous cells.

1.2. Nanomedicine
Nanoparticles may be broadly classified as inorganic or organic in nature, and are
able to take advantage of unique, size-dependent physico-chemical properties. Inorganic
nanoparticles include gold nanoparticles (AuNP), iron oxide nanoparticles (IONP),
carbon nanotubes (CNTs), quantum dots (QDs), or mesoporous silica. This class of
nanomaterial has found widespread biomedical application as local regulators of
hyperthermia, MRI contrast, or as fluorescent markers for cell labeling or imaging.
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Furthermore, inorganic nanoparticles have found application as drug delivery vehicles.
Drug molecules are covalently bound or physically adsorbed to the nanoparticle surface.
However, inorganic nanoparticles generally are limited as drug delivery vehicles due to
short drug release time (< 6hr) [37-39]. Moreover, covalent attachment or surface
adsorption of drug molecules to a nanoparticle is expected to alter in vivo
pharmacodynamics and biodistribution. Liu et al. [39] showed that CNTs functionalized
with poly(ethylene glycol) (PEG) had a circulation half-life of 3.3 hr. However
functionalization of PEG chain ends with paclitaxel (PTX) effectively mitigated the PEG
surface properties, and circulation time decreased to 1.1 hr. Another approach to loading
drugs into inorganic nanoparticles is to encapsulate drugs within a hollow core, or a
porous shell. Chen et al. [40] loaded doxorubicin (DOX) into hollow spindle-shaped
nanoparticles made of gadolinium sulfoxide and doped with terbium (Gd2O2S:Tb). These
particles were in turn coated with a thin layer of SiO and then coated layer-by-layer with
poly(styrenesulfonate sodium) (PSS), and poly(allylamine hydrochloride) (PAH) to
impart pH-dependent release of drug. While the polymer coating was able to effectively
low the release at pH 7.4, release at a lower pH 5 occurred within 48 hours. Similarly,
Kang et al. [38] synthesized sodium yttrium fluoride nanoparticles doped with terbium
and erbium (NaYF4:Tb,Eu) and coated with varying thickness layers of mesoporous
silica. Thus, while inorganic NP have found use for diverse imaging applications, organic
NP offer advantages for drug delivery through more efficient drug encapsulation,
controlling drug release, and biodegradability.
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Organic nanoparticles include polymers (polymeric micelles, solid polymeric
nanoparticles, polymer-drug conjugates, dendrimers, filomicelles) [22, 25, 41-43], lipids
(liposomes) [44], solid-lipid polymeric nanoparticles [45], or self-assembled peptide
nanoparticles [46]. Polymeric nanoparticles show much promise as drug delivery
vehicles. Genexol-PM (Samyang), a PLA-PEG polymeric micelle loaded with paclitaxel,
has entered phase IV clinical trials in the U.S. BIND Therapeutics, a U.S. company spun
out of Dr. Robert Langer’s lab at MIT, is currently developing their prostate cancer
targeted, docetaxel-loaded PLGA-PEG nanoparticle platform (Accurins™). Polymeric
PLGA-PEG nanoparticles have been shown in vivo to increase blood circulation time,
improve tumor reduction efficacy, and act as targeted therapies [22, 47-49]. With
advanced polymers, nanoparticles may utilize pH- or temperature-sensitive release [50,
51]. For imaging, polymeric nanoparticles generally require loading with a contrast agent
such as a fluorescent dye, iron oxide nanoparticles, or quantum dots [52]. However,
polymer dots have been described which have inherent fluorescent capabilities [53-55].
Robert Langer reported biodegradable, polymeric nanoparticles intended for drug
delivery as early as 1994 [48]. PCL-PEG and PLGA-PEG particles 90-150 nm in
diameter and capable of loading up to 45 w/w% of lidocaine, a model drug, were
synthesized. These particles were able to release lidocaine over 14 hours. PEGylation
increased circulation time, and 66% of uncoated PLGA particles were cleared via the
liver within 5 minutes while only 30% of PLGA-PEG particles were cleared after 2
hours. More recently, docetaxel (DTX)-loaded PLGA-PEG particles functionalized with
PSMA-targeted aptamer were shown to improve tumor targeting and therapeutic efficacy
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in vivo [22, 47]. After intratumoral injection in subcutaneous xenografts of LNCaP in
nude Balb/c mice, PLGA-PEG(DTX)-Apt were significantly more effective than PLGAPEG(DTX) and free DTX at reducing tumor volume. Histological tumor sections at 109
day endpoint showed that PLGA-PEG(DTX)-Apt completely reduced the tumor and
tumor was replaced by fibrotic tissue. In vivo studies by Kim et al. [56] discovered that
loading paclitaxel (PTX) in PLA-PEG particles increased the drug maximum tolerated
dose (MTD) from 20 mg/kg for free PTX to 60 mg/kg for PLA-PEG(PTX) in female SPF
C3H/HeNcrj mice. In tumor reduction models, PLA-PEG(PTX) administered at the MTD
of 60 mg/kg decreased the volume of SKOV3 human ovarian cancer xenografts in
athymic nude mice to 20% of initial tumor volume at ~25 days. Free PTX initially limited
tumor growth, but did not shrink tumor volume. Human MX-1 breast cancer xenografts
in Tac:Cr:(NCr)-nu athymic mice were completely reduced by treatment with 60 mg/kg
of PLA-PEG(PTX). Phase I clinical trials of PLA-PEG(PTX) in patients with metastatic
breast cancer determined the MTD to be 390 mg/m2 for 3 hours every 3 weeks with no
adverse effects [57]. Thus, nanoparticles are suitable as imaging agents and drug delivery
vehicles. While inorganic nanoparticles may be better suited for imaging applications and
organic nanoparticles better suited for controlled release drug delivery applications, some
nanoparticle platforms aim to merge these two applications into a single package.
Theranostics is a new field that aims to marry these two functionalities: therapy and
diagnostics.
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1.3. Theranostic Nanomedicine: Imaging Drug Delivery
Theranostic nanomedicines, systems that combine therapeutic and diagnostic
modalities into a single package, are expected to provide real-time information of a drug
delivery system’s biodistribution, drug concentration, or drug release kinetics. The
National Institute of Health (NIH) Challenge Grants in Health and Science Research, part
of the American Recovery and Reinvestment Act of 2009 outlined the urgent goal of
finding effective systemic treatments that can validate the localization of drug at the
tumor site in real time, i.e. smart, theranostic biomaterials.
First generation theranostic nanomedicines have focused on combining both
therapeutic and imaging modalities to image the localization of the drug delivery vehicle
at the tumor. These systems generally rely on nanoparticles with discrete imaging and
drug delivery components. In this approach, the imaging modality is independent of drug
delivery and may comprise a number of different nanoparticles (NPs). Magnetic NPs are
of considerable interest for theranostic applications due to their capacity for drug
delivery, controlled localization in vivo [58], and MRI contrast [59, 60]. Moreover,
magnetic NPs may be combined with other nanocarriers to impart optimal drug delivery
properties [61, 62]. Other systems capable of combined imaging and release include gold
nanoparticles (AuNP) [63], carbon nanotubes (CNT) [39, 64-66], quantum dots (QD) [37,
67], polymeric nanoparticles [52, 53, 68-71], nanobubbles [72], and liposomes [73].
While these exciting technologies offer approaches to combine imaging and drug
delivery, many lack the capacity to quantitatively measure drug release kinetics in real
time.
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Figure 1.2 Theranostic nanomedicine with real-time monitoring of drug biodistribution,
in situ concentration, and therapeutic efficacy would provide tools to clinicians to
monitor therapeutic efficacy and adjust treatment regimens accordingly.
Traditional pharmacokinetics approaches such as quantification of radiolabelled
drugs in tissue using positron emission tomography (PET), single photon emission
tomography (SPECT), or radiology of excised tissues are valuable for measuring total
drug accumulation rates in tissue. However, they cannot distinguish free drug that has
been released from a NP from encapsulated drug because they produce the same signal.
Consequently, a frontier of theranostics is to measure in situ release rates. Below, we
describe methods to detect drug release through tissue using MRI and optical techniques.
Table 1.1 shows a summary of the techniques advantages and limitations.
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Table 1.1 Summary of methods for measuring the release of drug from particles.
Method/Contrast
Agent

Advantages

Limitations

References

MRI/ T1 contrast increases
when Dox-Mn2+ complexes
are released from liposome

Noninvasive and sensitive
technique for quantifying
drug release in vivo, good
spatial resolution, and can
make measurements through
tissue.
Biodegradable, the pore size
and surface chemistry can be
tuned to change release rate,
multiple materials may be
encapsulated e.g. magnetic
materials for targeting.

Expensive and not
portable, drug
molecules have to be
MRI sensitive or be
conjugated to MRI
sensitive molecules.
Reflection spectrum not
observable through
thick tissue, requires
microstructures for
photonic crystal effect,
size is a limitation for
some applications.

74-77

Fluorescent drug
accumulation /singlet
oxygen luminescence

Instrument is inexpensive and
could be made portable.

87

Fluorescent nanoparticles

The instrument is
inexpensive and could be
made portable. Allows
targeting drug delivery and
release monitoring.

Upconverting nanoparticles

Upconverting nanoparticles
have high photostability and
low toxicity, NIR excitation
allows good tissue
penetration depth and
produces no autofluorescence
background.
Excitation source (X-ray)
generates no
autofluorescence
background, provides high
spatial resolution images and
allows deep soft tissue
penetration depth in vivo.

Accumulation in tumor
is nonspecific,
monitoring through
deep tissue is limited by
autofluorescence
background and light
attenuation in tissue,
spatial resolution is
limited by optical
scattering.
In vivo monitoring is
limited by the
autofluorescence
background and light
attenuation in tissue.
Spatial resolution is
limited by optical
scattering.
Penetration depth is
limited by the excitation
and emission
wavelength, the spatial
resolution of image is
limited by optical
scattering.
X-ray dose limits
detection depth and
image resolution.

Reflection: Porous silicon
photonic crystals change
color upon drug release.

Radioluminescent
nanoparticles
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90

37

38, 88

43, 114-115

1.3.1. Magnetic Resonance Imaging of Drug Release
Theranostic nanomedicines can employ drugs that are complexed with an imaging
agent. Thus, when the drug releases from the NP, the imaging agent is also released and
quantification of the imaging agent reports the release of drug. Viglianti and Dewhirst
[74-76] reported liposomes that encapsulated doxorubicin (DOX), an anthracyclines
anticancer drug, and manganese sulfate, an MRI contrast agent. Temperature sensitive
liposomes less than 200 nm in diameter were prepared to destabilize and release drug at
hyperthermic temperatures (39 °C to 40 °C) [77]. In this study, DOX molecules were
complexed with manganese ions (Mn2+), and these ions are able to act as T1-shortening
MRI contrast agents. Within the liposome, MRI contrast is diminished because T1shortening is dependent upon interaction of water with the Mn2+, and sequestration of
DOX-Mn2+ within the liposomes reduces the interaction of Mn2+ with water (Figure 1.3).

Figure 1.3 Thermal sensitive liposomes are destabilized when temperature is increased.
This results in the release of manganese-doxorubicin complexes that are measured via
magnetic resonance imaging.
In this study, rats were implanted subcutaneously with rat fibrosarcoma tumors,
and liposomal treatments were administered intravenously [76]. Treatment groups
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included hyperthermia (HT) + temperature-sensitive liposomes (TSL), no hyperthermia
(nHT) + TSL, HT + non-temperature-sensitive liposome (nTSL), and nHT + nTSL. T1weighted MRI images were compared to HPLC analysis and fluorescent histological
analysis of explanted tumor tissues after treatment with liposomes. HPLC data showed a
strong correlation in drug concentration with image analysis of MRI contrast agents in
tissue, indicating that MRI was a sensitive, non-invasive modality to measure the
hyperthermia-mediated release of DOX in vivo. This approach was able to measure DOX
release in vivo at µg/ml concentrations. This approach has the benefit of being able to
quantify drug release in deep tissue.
Because some research has raised questions about the cytotoxicity of manganese
ions, work has pushed for a gadolinium-based theranostic system [78, 79]. Gadolinium is
in clinically approved MRI contrast agents at concentrations as low as 0.1 mmol per kg
body mass [80].

Figure 1.4 Temperature sensitive liposomes also encapsulated the imaging agent GdDTPA and anticancer drug doxorubicin. Upon application of heat, liposome integrity is
ruptured which releases both drug and imaging agent.
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Tagami et al. [81] reported temperature sensitive liposomal formulations that coencapsulated DOX and a gadolinium-diethylene triamine pentaacetic acid complex (GdDTPA). In this study DOX is not complexed with the gadolinium ions, and DOX release
is instead modeled by the release of Gd-DTPA. Gd-DTPA showed similar release
kinetics to DOX in vitro. At 30 °C and 37 °C there was no detectable release of GdDTPA over 30 minutes, while at 40 °C and 42 °C there was total Gd-DTPA release
within 3 minutes. DOX release showed similar results where 100% DOX was released
within 3 minutes at 40 °C and 42 °C. Fluorescent readings of explanted tumor tissue
showed a strong correlation between DOX in tissue and Gd-DTPA content measured via
MRI. Furthermore, liposomal formulations combined with hyperthermia-mediated DOX
release were able show a dose-dependent inhibition of tumor growth in vivo. Thus, these
two studies illustrate a potential mechanism whereby MRI could measure drug release
non-invasively.

1.3.2. Optical Approaches to Measuring Drug Release
Theranostic nanotechnologies with the ability to quantitatively measure the
release of drug would provide critical data regarding delivered drug dose in real time.
Non-invasive optical methods are often used to monitor concentration of fluorescent drug
in tumors [82-86]. In order to measure drug release rate independent of NP accumulation,
the free drug must have a different spectral signature when released versus when
encapsulated. The most common approach relies on fluorescence quenching of the drug
when encapsulated in the NP due to self-quenching at high concentration or energy
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transfer to a quencher such as another dye or a gold NP. Release of the drug from the NP
results in increased fluorescence intensity. Other methods rely upon distance dependent
inner filter absorption effects, changes in the local refractive index in photonic crystal
structures, and methods to magnetically modulate the dye only when it is attached to the
particle [37, 40, 76, 87, 88].

1.3.2.a. Porous silicon photonic crystals
Silicon is a material that can be patterned with electrochemical and lithographic
technique to generate very versatile drug carriers. For example, silicon can be
electrochemically etched to generate nanopores that can be loaded with drugs. The width
of the pores can be controlled during electrochemical etching to produce rugate structures
with sharp spectral reflection features, similar to the photonic patterns in beetles and
butterflies [89]. Porous silicon (PSi) microparticles have been shown to quantitatively
measure the release of the anticancer drug daunorubicin (DAU) [90]. Plate-shaped
microparticles approximately 12 µm by 35 µm were loaded with daunorubicin by
covalently linking the drug to the microparticle surface via 1-undecylenic acid.
Dissolution of the PSi microparticle resulted in zero-order release kinetics of DAU and
orthosilic acid. Moreover, PSi dissolution resulted in a shift in the λmax reflectivity spectra
of the particles. Thus, the colorimetric shift in λmax could be directly correlated with the
release of daunorubicin. To further verify that daunorubicin release was mediated by the
dissolution of PSi microparticles, DAU-conjugated microparticles were incubated in pH
5, pH 7, pH 9. More alkaline pH catalyzed the dissolution of PSi, and DAU release
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studies showed that increasing pH lead to more rapid release of orthosilicate and
daunorubicin. Increasing pH also lead to more rapid spectral peak shift. Thus, porous PSi
microparticles enable the quantitative measure of drug release.

Figure 1.5 Porous silicon (PSi) particles can be loaded with daunorubicin via covalent
conjugation. PSi particles exhibit narrow reflectance spectra, and when loaded with drug
reflect visible light at distinct wavelengths. PSi dissolution causes a blue shift in the
spectrum.
PSi has also demonstrated inherent photoluminescent properties which may be
amenable for in vivo imaging applications [91-95]. Park et al. [92] described luminescent
porous silicon NPs approximately 126 nm in diameter and coated with dextran. PSi NPs
were able to load 4.4 wt% DOX via the electrostatic interaction between drug and the
porous silicon nanoparticles. NPs mediated the release of doxorubicin over a 10-hour
period. Furthermore, PSi NPs were photoluminescent with an excitation wavelength in
the ultraviolet region (370 nm), and emission maximum around 800 nm. PSi NPs were
also biodegradable and dissolved within 8 hours in phosphate buffered saline. As PSi NP
degraded their photoluminescent intensity not only decreased, but also exhibited a
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blueshift of the luminescence spectrum. However, PSi NPs were not shown to enable
quantitative imaging of doxorubicin release.
Thus, PSi particles are another platform for imaging drug release. While use of
photoluminescence to image was not shown to quantitatively measure drug release from
PSi NPs, [92] spectral reflectance was shown to directly measure the release of DAU
from PSi microparticles [90]. However, imaging reflectance in vivo to measure drug
release would be limited.

1.3.2.b. Fluorescent drug accumulation and singlet oxygen luminescence
In some instances, the drug itself serves as the imaging and therapeutic agent.
This can be attributed to inherent imaging properties of the drug. For instance, pHsensitive NPs comprised of poly(ethylene glycol)-co-poly(β-amino ester) (PEG-PBA)
were shown to deliver the photosensitizer protoporphyrin IX (PpIX) for combined
photodynamic therapy and imaging [87]. In this system, PEG acts as a NP-stabilizing
corona and PBA loads the hydrophobic drug. PBA is protonated at its tertiary amine at
lower pH, causing the polymeric micelle to destabilize and release its PpIX payload.
Aside from being a photoactive drug, PpIX is also a fluorescent molecule and can
therefore be used for imaging. The PpIX fluorescence is quenched by molecular oxygen,
thereby generating singlet oxygen, which believed to be the primary effector responsible
for killing cells. This system confers three types of information: the PpIX can be
localized based upon fluorescence microscopy and optical tomography, the local
dissolved oxygen concentration can be measured based upon the fluorescence lifetime
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[96], and the amount of singlet oxygen generated during photodynamic therapy can be
measured by detecting the singlet oxygen luminescence at 1270 nm [97, 98]. In vitro
fluorescence measurements showed a pH-dependent release of PpIX over a 72-hour
period with up to 60% of drug released within the first 24 hours at pH 6.4. At
physiological pH of 7.4 only 20% of drug was released after 72 hours. Fluorescent
imaging of SCC7 squamous cell carcinoma in vitro showed more uptake of PpIX at lower
extracellular pH. This is ostensibly due to the destabilization of PBA-PEG micelles and
release of the PpIX payload when internalized via lysosomes. Subcutaneous SCC7 tumor
xenografts showed accumulation of PpIX-loaded PBA-PEG NPs in tumors. 5 mg PpIX
per kilogram of mouse mass was injected via the tail vein as either free PpIX or PpIX
encapsulated in PBA-PEG NPs. PpIX was imaged fluorescently using a 670 nm pulsed
laser diode excitation source. Kinetic fluorescent biodistribution studies showed an
increased accumulation of PpIX in tumor tissue over a 48-hour period when delivered via
the PBA-PEG nanoparticles, as opposed to free PpIX. The relative fluorescent intensity
of PpIX was calculated as 10 fold higher in tumors when administered via NP compared
to free drug. Explanted tissues showed an appreciable accumulation of PpIX in the liver
tissue for the free PpIX while PpIX delivered via PBA-PEG showed strong fluorescent
signal in the explanted tumor. This platform shows potential for the quantitative
monitoring of drug delivery in vivo based on the fluorescent properties of the drug
molecule. It was shown to be effective in SCC7 squamous cell carcinoma to treat
superficial, subcutaneous tumor grafts. However, feasibility of this therapy in a deeper
tissue was not explored and is likely to be limited because the 670 nm excitation
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wavelength is attenuated by a factor of between 10 and 1000 per cm of tissue depth,
depending on the type of tissue [99]. Treatment of tumor 1 cm and deeper would
therefore require either an endoscopic light source or a method to apply light over a
period of days.

Figure 1.6 pH-sensitive PBA-PEG nanoparticles are loaded with the photoactive drug
protoporphyrin IX (PpIX). This drug also has a fluorescent spectrum and measuring
fluorescent signal in tissue can quantitate the relative amount of drug. Decrease in
intratumoral pH causes protonation of PBA, which results in destabilization of the
nanoparticle and release of PpIX.
1.3.2.c. Fluorescent Nanoparticles
A different approach to employing fluorescence as a theranostic modality is to
utilize fluorescent NPs. Bagalkot et al. [37] reported a QD drug delivery system in which
fluorescence resonance energy transfer (FRET) allows for fluorescent imaging of both
nanoparticles and delivery of drug. DOX was employed as the drug model due to its
inherent fluorescence. Here, the QD are functionalized with a double-stranded A10 RNA
aptamer that intercalates DOX and specifically binds prostate specific membrane antigen
(PSMA). The QD-aptamer-Dox construct (QD-Apt(DOX)) is “turned off” because DOX
quenches the fluorescent emission of the QD, and the aptamer quenches the fluorescent
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emission of DOX. Upon the release of drug both entities become fluorescent, allowing
for the visualization of both nanoparticle and drug location. PSMA is overexpressed in
LNCaP human prostate cancer cells but not PC3 human prostate cancer cells; therefore,
LNCaP cells were qualitatively shown to uptake more QD-aptamer (QD-Apt) conjugates
than PC3 cells in vitro. After incubating LNCaP cells for 30 minutes with QDApt(DOX), cells were washed and imaged with confocal microscopy. At this time, cells
showed no fluorescence, indicating a lack of drug release. However, after incubating for
1.5 hours more fluorescent signal could be seen in the cell from both Dox and QD. Thus,
the QD-Apt(Dox) conjugate could be used to image the release of drug in vitro.
Moreover, QD-Apt were sensitive to the quantity of Dox loaded. QD-Apt held at a fixed
concentration (1 µM) were incubated with increasing amounts of Dox, and maximum
FRET quenching was observed at a QD-Apt:Dox ratio of 1:7. As a chemotherapeutic
agent, QD-Apt(Dox) conjugates at 1.6 µM were approximately as effective as free Dox at
5 µM. Savla et al. [100] employed a similar system to improve the delivery of free Dox to
A2780/AD multidrug resistant human ovarian cancer in vitro and in female athymic
nu/nu mice. QD were conjugated to an aptamer (MUC1) which targets mutated Mucin 1,
a cell surface-associated mucin overexpressed in late stage epithelial ovarian cancer. Dox
was conjugated via an acid-degradable hydrazone bond. Similar to the Bagalkot study,
QD-MUC1(Dox) conjugates displayed FRET extinction of QD fluorescence. Free Dox,
QD-Dox, and QD-MUC1(Dox) showed similar treatment efficacy in vitro. In vivo,
targeted QD-MUC1 showed higher uptake compared to untargeted QD. No tumor
volume reduction data was reported for in vivo efficacy. The primary utility of these two
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systems from a theranostic drug delivery system standpoint is as an “on/off” switch
indicating drug loaded or released. Compared to polymeric systems in which drug is
encapsulated, these systems load much lower amounts of drug and have relatively quick
release. One limitation related to in vivo imaging is associated with poor penetration of
excitation wavelengths through tissue. Although this system is unable to measure the
release kinetics based on FRET extinction, other systems capable of dynamically
measuring release rates have been developed.
Rare earth-doped nanophosphors are a class of inorganic materials that are able to
convert various forms of electromagnetic radiation into visible light. Different classes of
nanophosphors can convert ultraviolet light (fluorescent phosphors), infrared light
(upconversion phosphors), or x-ray (radioluminescent phosphors) into visible light.

Figure 1.7 Bi-fluorescence resonance energy transfer enables the measure of drug
loading onto quantum dot-aptamer conjugates. Doxorubicin, a fluorescent anticancer
drug, binds the prostate cancer targeting aptamer. Doxorubicin quenches the fluorescent
signal from the quantum dot, and the targeting aptamer quenches fluorescence from
doxorubicin. Upon release, both entities regain their fluorescence.
Nanophosphors are advantageous compared with organic dyes because these rare earthdoped inorganic phosphors have a high chemical stability and do not photobleach or fade
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[101, 102]. Nanophosphors also have narrow and distinct spectra, similar to quantum dots
[103], however their low toxicity draws attention to their biological applications [103105]. Xu et al. [106] developed a system that employs NPs with short ultraviolet (256
nm) excitation wavelength and emission of visible light (613 nm) to measure drug
loading and release. NPs were composed of a spherical europium-doped gadolinium
oxide core (Gd2O3:Eu3+) approximately 270 nm within a mesoporous silica
(@nSiO2@mSiO2) shell approximately 50 nm thick. DOX is able to load at 8.56 wt%
within the pores of the mesoporous silica and quench the luminescent emission signal of
the Gd2O3:Eu3+. Release studies revealed that Gd2O3:Eu3+@nSiO2@mSiO2 NPs released
80% of loaded DOX over 12 hours. The photoluminescence of the Gd2O3:Eu3+ was
measured as DOX was released. These simultaneous studies of NP luminescence and
DOX release showed a direct relationship between the amount of Dox released and
increasing NP photoluminescent intensity. These results indicate that the Gd2O3:Eu3+
quenching effect of DOX is mitigated as it is released from the mesoporous silica shell,
and photoluminescence returns. In vitro studies of Gd2O3:Eu3+@nSiO2@mSiO2 NPs in
HeLa cervical cancer cells showed no concentration dependent toxicity up to 2.5 µg/ml.
Free Dox and DOX-loaded NPs showed equivalent efficacy in vitro against HeLa cells.
This system is limited for translation to in vivo diagnostics because the UV excitation
wavelengths are strongly absorbed by melanin in skin [107-109]. Furthermore, high
energy UV radiation has deleterious effects on DNA and may lead to protein-DNA
crosslinking, oxidative damage, and gene mutations [110].
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1.3.2.d. Upconversion Nanoparticles
Visible and UV light phosphors are expected to have limited application for deep
tissue imaging due to light scattering and the poor penetration depth of shorter excitation
wavelengths [111]. Recent research is focused on upconversion NPs, particles that can
convert longer near-infrared (NIR) wavelength light to visible light. Upconversion probes
capable of excitation at longer wavelengths and emission within the optical transmission
window (650-950 nm) are promising due to low tissue auto-fluorescence, deeper tissue
penetration of excitation wavelengths, and lower light scattering [112]. Chen et al. [112]
showed that upconversion particles could image as deep as 3.2 cm through pork tissue
with excitation at 980 nm and emission at 800 nm. Upconversion NPs have been
investigated as a means to track drug release by measuring luminescent intensity [38,
113].

Figure 1.8 Nanoparticle visible light luminescence, which may be excited by NIR light,
is attenuated by loaded drug. As drug is released, nanoparticle luminescence returns.
These systems enable quantitative measure of drug release.
Kang et al. [38] described an upconversion NP composed of sodium yttrium
fluoride (NaYF4) doped with ytterbium and erbium (Yb3+, Er3+). Similar to the previously
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mentioned Gd2O2:Eu3+ NP, the NaYF4:Yb3+/Er3+ were coated with mesoporous silica
(@nSiO2@mSiO2). In this system Ibuprofen (IBU) was chosen as a model drug and
loaded into mesoporous silica. The NaYF4:Yb3+/Er3+ core was 120 nm in diameter and
coated with a tunable level of mesoporous silica (10, 20, or 45 nm). These NPs were
capable of loading 11, 21, or 34 wt % IBU in the 10, 20, or 45 nm mesoporous silica
coatings, respectively. All three formulations demonstrated controlled release over a 10hour period, with changes in release kinetics altered by coating thickness. Thicker
coatings were hypothesized to slow release time due to the IBU having to travel farther
through the mesoporous silica. IBU also effectively quenched the photoluminescence
from the upconversion NaYF4:Yb3+/Er3+@nSiO2@mSiO2 nanoparticles. Nanoparticles
were excited by 980 nm wavelength light and had three emission peaks at 520, 550, and
650 nm. Release kinetics were directly correlated to the return of photoluminescence,
indicating that as IBU was released, the quenching effect of IBU diminished. This system
demonstrates a mechanism by which the release of drug can be dynamically measured
due to the quenching of NP luminescence by the drug. This system successfully shows a
robust method for quantitatively measuring drug release based on the upconversion
luminescence of NPs. However, as with most inorganic delivery systems, the release
kinetics are not optimized for controlled release. With the thickest mesoporous silica
coating, 75% of IBU was released within 12 hours. Upconversion NPs are expected to
overcome some of the challenges for in vivo imaging associated with fluorescent
molecules or NPs, but will still be limited in the penetration depth of the excitation and
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emission wavelength. Methods to improve drug loading and release kinetics have been
investigated using organic coatings on inorganic NPs.
Upconversion NPs have also been coated with organic layers to improve
lipophilic drug loading and aqueous dispersion [88]. In this study, cubic 20-30 nm
NaYF4:Yb/Er NPs were capped with oleic acid and further functionalized with αcyclodextrin (αCD). Oleic acid was able to load lipophilic photosensitizers such as
Chlorin e6 (Ce6), Zinc phthalocyanine (ZnPc) and Methylene blue (MB). α-Cyclodextrin
improves the aqueous solubility of this system, and cyclodextrin has been used in clinical
trials as part of a nanoparticle drug delivery system [69, 70]. In this system, the
upconversion particles were excited by a 980 nm laser, then they emitted strongly in the
650-670 nm range. Ce6, ZnPc, and MB had strong absorptions in this region. Loading
capacity for all three photosensitizers was dependent on the loading photosensitizer
concentration, and total loading between drugs was variable. This is possibly due to
differences in drug chemical structure. Ce6, ZnP, and MB were able to load at 0.158,
0.165, and 0.129 mmol/g, respectively. Luminescent intensity of the NPs was quenched
by loading the photosensitive drug, and the release of photosensitizer allowed for a
dynamic method to measure drug release. Release studies showed that approximately
10% of drug was released in 48 hours.
In vitro toxicity of photosensitizer-loaded upconversion NPs was shown in A-549
adenocarcinomic human alveolar basal epithelial cells. Photosensitizer-loaded NPs
without laser irradiation showed no significant toxicity in cells. However, when irradiated
with the 980 nm laser (1 W/cm2) for 3 minutes, upconversion luminescence activates the
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photosensitive drug, creating reactive oxygen species and the irradiated NPs showed
dose-dependent toxicity in vitro. Toxicity was also dependent on the duration of laser
irradiation. This photodynamic therapy could be combined with traditional chemotherapy
by loading Dox in the nanoparticle. The combination of Dox and photodynamic therapy
significantly improved therapeutic efficacy of the NP. For example, NPs loaded with
0.077 mmol/g of Ce6 and 0.082 mmol/g Dox irradiated with 980 nm laser showed
approximately 15% cell viability with A-549 cells in vitro. This was significantly better
than NPs loaded with Ce6 and Dox without irradiation (~40% cell viability) or Ce6 NPs
with irradiation (~40% cell viability). While these treatments are effective in vitro, nearinfrared and infrared wavelengths are still limited in translation to deep tissue imaging
because the penetration depth is on the scale of millimeters [111]. Technologies with
greater potential to penetrate deep into tissue are expected to improve theranostic
modalities.

1.3.2.e. Radioluminescent Nanoparticles
Radioluminescence is a phenomenon whereby radiation energy is converted into
visible light. The benefit of using this type of system for measuring drug release is that xray has excellent soft tissue penetration. Thus, the excitation wavelength is not limited in
penetration depth. Radioluminescent nanophosphors have been investigated for in vivo
imaging and as quantitative sensors for drug delivery [40, 114, 115]. Chen et al. [40]
described radioluminescent NPs coated with poly(styrenesulfonate sodium) (PSS) and
poly(allyl-amine HCl) (PAH) via a layer-by-layer assembly, which imparts a pH-
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sensitive drug release. The hollow nanoparticle was comprised of gadolinium oxysulfide
(Gd2O2S) doped with terbium (Tb) and europium (Eu). NPs were ellipsoidal in shape
with an average length of 420 nm and a width of 150 nm. Higher aspect ratio NPs have
been shown previously to extend plasma circulation time in vivo [25, 116, 117]. The
Gd2O2S:Tb-PSS/PAH NPs were able to load ~5 wt% DOX, and release measured by high
performance liquid chromatography directly correlated with peak quenching of the NP
radioluminescence. Moreover, DOX release was shown to be pH dependent with rapid
release at pH 5.0 and slow release at pH 7.4. The goal of pH dependent release is to
exploit intracellular release of drug in endosomes or lysosomes after endocytosis. NP
uptake was shown in MCF-7 breast cancer cells, and in vivo biodistribution showed the
ability to dynamically and non-invasively monitor radioluminescent nanoparticle
accumulation in the liver of Balb/c mice. Previous studies have shown the ability of
radioluminescent NPs for deep tissue imaging in chicken breast after injection deeper
than 1 cm [114]. This system offers a promising platform for theranostic nanomedicine
due to excellent penetration depth of x-rays through soft tissue.

Figure 1.9 Radioluminescent Gd2O2S nanoparticles doped with terbium and europium
(Gd2O2S:Tb/Eu) were coated layer by layer with poly(styrenesulfonate sodium) (PSS)
and poly(allyl-amine HCl) (PAH). These hollow nanoparticles were able to encapsulate
doxorubicin and exhibit pH dependent response. Doxorubicin attenuates
radioluminescence. Luminescence returns in intensity proportional to doxorubicin
release.
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A key advantage of this approach is that there is almost no autofluorescence
background and the radioluminescence is only generated where the x-ray beam irradiates
the tissue. By irradiating the tissue with a collimated or focused x-ray beam, it is possible
to map the spectrum point-by-point in order to generate high resolution images, limited in
resolution by the x-ray beam width. This is in contrast to fluorescence excitation, wherein
the excitation beam is scattered with a typical mean free path of ~100 µm, and the almost
all the light passing through more than 1 mm of tissue propagates diffusively providing a
point spread function with a width similar to the tissue depth [118, 119].
The main limitation of the x-ray excited optical luminescence imaging is that
radioluminescent systems may be limited by the penetration depth of visible light
emissions, even though x-rays have excellent soft tissue penetration. In general, there is a
tradeoff between the required x-ray dose and the scintillator concentration, the depth of
the scintillators in the tissue, and the spatial resolution of the image. For example, in a
numerical
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concentrations of 10 nm X-ray phosphor are detectable for a mammographic-like dose
with a signal/noise level of 10 [120]. For applications such as tumor-resection where the
X-ray excitation angle is limited by geometry, and where increased rapid acquisition is
critical, a limited-angle X-ray luminescence tomography (XLCT) can be applied based on
a hybrid X-ray/optical reconstruction. In XLCT X-rays pencil-like X-rays are used to
excite scintillators in a narrow region defined by the beam diameter, and diffuse optical
spatial discrimination for the axial dimension along the beam. According to their model,
µg/mL particle concentrations may be observed through 5 cm of tissue with ~10 mGy
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doses [121]. Even more rapid images can be acquired using a cone-angle geometry with
multiple angle views, but the resolution will be limited by the optical scattering in the
tissue [122].
Nanophosphors (luminescent nanoparticles) exist as a potential platform for a
theranostic system able to quantitatively measuring drug delivery has been shown at the
bench. These NPs can be tailored to have excitation wavelengths over a broad range,
from x-ray to near infrared light. Employing NPs with luminescence that overlaps with
the optical properties of drugs has been shown to quantitatively measure the release of
drug. The use of these NPs in a clinical sense is still limited by specific challenges,
namely nanoparticle-associated toxicity and physical limitations. Currently optical
imaging in tissue is limited to the millimeter or centimeter depth. MRI imaging
techniques rely on indirect approaches which model drug delivery based on the codelivery of MRI contrast agents, or rely on the conjugation of imaging agent to drugs
which could alter release kinetics or efficacy. Thus, identifying and addressing current
imaging challenges will guide decisions for future research.

1.4. Challenges in Theranostic Nanomedicine
Real challenges exist with the development of theranostic nanomedicines to
enable non-invasive measurement of drug delivery. Nanomedicines must demonstrate
reasonable safety. Many particles used for imaging have shown success in vitro for
cellular labeling but are limited in translation to more complex living systems due to
toxicity.
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1.4.1. Factors Affecting Nanoparticle Toxicity
A primary challenge surrounding the use of nanoparticles for biomedical
applications is the selection of material that optimizes the NP’s intended function, but
mitigates nanomaterial-related toxicity. For example, quantum dots (QD) have garnered
much excitement for use as in vitro fluorescent tags, however concerns about their
toxicity arise because QDs are generally made out of heavy metal elements such as
cadmium selenium (CdSe), cadmium tellurium (CdTe), and zinc selenium (ZnSe) [123].
While QD generally have a core-shell structure to reduce cytotoxicity, investigations into
the leaching of heavy metals from QD via oxidation showed toxicity in vitro [124]. CdSe
QD oxidized in air or with UV light showed a red shift in fluorescence, indicating a
change in size because of the leaching of surface atoms due to oxidation. QD kept in an
inert environment, i.e. no oxidation, showed no toxicity in vitro against primary rat
hepatocytes. However, when oxidized in air for 30 minutes cell viability decreased to
21% at a QD concentration of 62.5 µg/ml. Free Cd2+ concentrations were determined
from oxidized QD samples via inductively coupled plasma optical emission
spectroscopy. QD oxidation in air resulted in a 21-fold increase in Cd2+ concentration,
from 6 ppm to 126 ppm. Therefore it can be surmised that toxicity is in part related to
nanomaterial composition and stability.
Some nanomaterials have a historic track record for biocompatibility and have
entered clinical trials. Gold, for example, has long been used as a biomaterial because it is
relatively bioinert and stable [125], and gold nanoparticles (AuNP) have been employed
as a therapeutic since the 1930s as treatment for rheumatoid arthritis [126, 127]. Gold
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nanoshells meant to mediate hyperthermia have seen success in vivo, and a company
developed on this technology platform (Nanospectra Biosciences, Inc.) has begun clinical
trials of AuNP for thermal ablation of solid tumors [128-130]. In fact, tissue necrosis
factor α (TNFα)-bound AuNP functionalized with PEG showed no adverse events in
human clinical trials with concentrations from 50 µg/m2 to 600 µg/m2 [131]. Magnetic
iron oxide nanoparticles (IONP) have also shown promise as non-toxic nanomaterials. In
vitro studies with RAW 264.7 rat macrophages indicated that 9 nm IONP induced
oxidative stress, however cell viability and growth was not hindered [132]. Clinical trials
for superparamagnetic and ultra-small IONP exist, and the Food and Drug Administration
(FDA) has approved Ferumoxtran-10 (AMAG Pharmaceuticals), a formulation of monodispersed 5 nm IONP with a ~15 nm coating of dextran, for MRI contrast. Phase II
clinical studies of intravenously administered Ferumoxtran-10 showed no significant
events with doses up to 1.7 mg Fe/kg [133, 134]. Thus, nanomaterial stability in vivo
seems to be important in determining NP toxicity. AuNP are considered bioinert and
relatively non-toxic. QDs, however, have been shown to leach toxic metal ions leading to
cytotoxicity. Thus, determining the stability and degradation of a nanomaterials will be
key to preventing unintended toxicity.
NP size and shape is also relevant in determining toxic response. Altering NP size
and shape has been shown to greatly influence circulation time, biodistribution, toxicity,
and cellular uptake [25, 30, 41, 116]. Carbon nanotubes (CNT) are a prime example of
nanomaterials in which toxicity is closely related to size and morphology. Several studies
indicate that CNTs are safe when injected intravenously, and it appears that toxicity,
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fibrosis, and chronic inflammatory response are mediated by the size and morphology,
route of administration, dose, and surface functionalization [135-141]. Tang et al. [142]
showed that carbon-based nanomaterials such as carbon nanocapsules (CNCs), C60
fullerene (C60), multi-walled carbon nanotubes (MWCNT), and single-walled carbon
nanotubes (SWCNT) had different toxicity profiles due to differences in size and shape.
Carbon nanomaterials were dispersed in 1 wt% polyvinyl alcohol (PVA) and
administered via tail vein injection. In both MWCNT and SWCNT no mice survived after
receiving 50 µg/g, however 50% of mice receiving C60 and 91.7% of mice receiving
CNCs survived at this dose.
Gold nanoparticles, on the other hand, show little toxicity associated with size and
shape. In vitro studies with 4, 12, and 18 nm diameter nanoparticles tested against K562
leukemia cells showed no toxicity up to 250 µM concentration [143]. Moreover shape
does not seem to play as large a role in AuNP-mediated toxicity. PEGylated gold
nanorods approximately 65 nm long and 11 nm in diameter were injected at a
concentration of 0.9 mM Au atom into male ddY mice, and at various time points, mice
were euthanized and organs were collected [144]. Gold content was quantified via ICP
mass spectrometry, and gold nanorods had a circulation half-life of approximately 1 hour,
and were found up to 24 hours in the blood. At 72 hours, nanorods were absent from
blood and 35% of initial injected dose had accumulated in the liver. In summary,
nanoparticle-mediated toxicity appears to vary significantly between nanomaterial, size,
shape, aggregation, and degradability.
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1.4.2. Optical Challenges in Theranostic Nanomedicine
Furthermore, theranostic particles must overcome physical limitations with
respect to penetration depth of light due to scattering, and developing sensitive methods
to image drug or nanoparticle. The previously described theranostic approaches are
limited by drug modification, interaction of NPs and drugs, and optical imaging
capabilities in deep tissue. With optical techniques in tissue imaging, viable wavelengths
are generally restricted to the “biological window,” a range of wavelengths from 6501400 nm; we will refer to the spectral region from 650-1000 nm as the first optical
window, and the region from 1000-1400 nm as the second optical window [66, 111, 145148]. Wavelengths before 650 nm are strongly absorbed by hemoglobin, and those above
950 nm light begin to be absorbed by water [145, 149]. Imaging in the first optical
window can be hindered by autofluorescence and tissue scattering [111]. However,
imaging in the second optical window has shown promise with low incidence of
autofluorescence and tissue scattering. Hongjie Dai’s group has developed single-walled
carbon nanotubes capable of sensitive in vivo imaging in the second optical window, [65,
66] and Won et al. [148] showed significant improvement with imaging quantum dots in
the second optical window compared to the first optical window. Moreover,
upconversion NPs for deep tissue imaging have been developed which are capable of
imaging as deep as 3.2 cm through tissue [112]. However, approaches to image drug
release in the biological window must rely on drugs and NPs that are either photoactive
or absorb within this range of wavelengths. In the previously stated examples of NP
systems that measure drug release based upon FRET, the NP must be excited by a light

33

which can penetrate deep into tissue. The drug must also be such that its absorption
profile overlaps with the nanoparticle’s emission wavelength within this window.
Moreover, to get meaningful data from a complex and dynamic in vivo system, the
emitted light must overcome tissue scattering and be detected with enough sensitivity to
measure drug release. The power of the excitation wavelength source and its distance to
the NPs, the spatial distribution of the NP drug delivery system within the patient, and the
sensitivity of the luminescent detection will complicate detection sensitivity in a deep
tissue living system.
A relevant goal for drug delivery aims to non-invasively determine drug
concentration or release in tissue. This is possible with sensitive molecular imaging
techniques. Preclinical studies with the cyclodextrin polymer based nanoparticle
(CRLX101) with polymer-conjugated camptothecin showed that biodistribution could be
monitored using
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Cu-labeled polymer [70]. While CRLX101 has advanced to early

clinical trials, no efforts to pursue the positron emission tomography (PET) imaging
aspect for a theranostic drug delivery approach have been reported. Use of PET is also
limited due to cost and the short half-lives of radioisotopes: from 2 min with 15O to 109.8
min with 18F [150, 151]. Positron emitters with longer half-lives (e.g. 8.3 h for 52Fe and
4.2 days for
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I) are less commonly used because these elements are not found in many

drugs and require a higher energy synchrotron to produce. Ideally, a theranostic
nanomedicine to measure drug release will avoid modification of the drug, as this may
affect release kinetics, biodistribution, and activity. Measuring the release of drug using
MRI required complexing DOX with manganese ions [76], and the study employing Gd-
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DTPA only modeled the release of DOX but did not measure its release from liposomes
directly [81]. Thus, finding a way to measure drug release without drug modification
remains a challenge in theranostic nanomedicine.

1.5. Conclusions
Theranostic nanoparticles for non-invasive measurement of in situ drug release
are being realized in laboratory studies. Current approaches are able to utilize drugs
complexed with MRI contrast agents or take advantage of optical properties of drugs to
measure drug release non-invasively. Nanotechnologies offer a platform to realize noninvasive measurement of drug concentrations, improve drug delivery and imaging of
solid tumors, and improve drug biodistribution and efficacy. However, significant
challenges in theranostic nanomedicine must be overcome, namely the physical
limitations of optical methods, complexities in imaging sensitivity and resolution in deep
tissue, and toxicity of nanomaterials.

35

1.6. References
1.
Heidel JD, Davis ME. Clinical developments in nanotechnology for cancer
therapy. Pharm Res. 2011; 28: 187-99.
2.
Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al.
SEER Cancer Statistics Review, 1975-2009. In: KA C, editor. Bethesda, MA: National
Cancer Institute; 2011.
3.

Society AC. Cancer Facts & Figures. Atlanta: American Cancer Society; 2012.

4.
Gillet J-P, Gottesman M. Mechanisms of Multidrug Resistance in Cancer. In:
Zhou J, editor. Multi-Drug Resistance in Cancer: Humana Press; 2010. p. 47-76.
5.
Grantab RH, Tannock IF. Penetration of anticancer drugs through tumour tissue
as a function of cellular packing density and interstitial fluid pressure and its modification
by bortezomib. BMC Cancer. 2012; 12: 214.
6.
Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass
for cancer? Nat Rev Cancer. 2012; 12: 323-34.
7.
Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, Marioni JC, et
al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary
dynamics. Proceedings of the National Academy of Sciences. 2013.
8.
Kircher MF, Hricak H, Larson SM. Molecular imaging for personalized cancer
care. Molecular Oncology. 2012; 6: 182-95.
9.
Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for
cancer therapy. Handb Exp Pharmacol. 2010: 55-86.
10.
Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev
Clin Oncol. 2010; 7: 653-64.
11.
Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase
II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of
paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Annals of
Oncology. 2007; 18: 2009-14.
12.
Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron
oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsil. Mag Res Imaging.
1995; 13: 661-74.
13.

Hanahan D, Weinberg R. The Hallmarks of Cancer. Cell. 2000; 100: 57-70.

36

14.
Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer.
2006; 6: 583-92.
15.
Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic
applications. Nat Rev Drug Discov. 2010; 9: 615-27.
16.
Fukumura D, Jain RK. Tumor microenvironment abnormalities: Causes,
consequences, and strategies to normalize. Journal of Cellular Biochemistry. 2007; 101:
937-49.
17.
Campbell RB. Tumor Physiology and Delivery of Nanopharmaceuticals. AntiCancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - AntiCancer Agents). 2006; 6: 503-12.
18.
Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using
intravital microscopy. Nat Rev Cancer. 2002; 2: 266-76.
19.
Maeda H. The enhanced permeability and retention (EPR) effect in tumor
vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in
Enzyme Regulation. 2001; 41: 189-207.
20.
Matsumura Y, Maeda H. A New Concept for Macromolecular Therapeutics in
Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the
Antitumor Agent Smancs. Cancer Research. 1986; 46: 6387-92.
21.
Hassid Y, Eyal E, Margalit R, Furman-Haran E, Degani H. Non-invasive imaging
of barriers to drug delivery in tumors. Microvascular Research. 2008; 76: 94-103.
22.
Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted
nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the
National Academy of Sciences. 2006; 103: 6315-20.
23.
Chithrani BD, Ghazani AA, Chan WCW. Determining the Size and Shape
Dependence of Gold Nanoparticle Uptake into Mammalian Cells. Nano Letters. 2006; 6:
662-8.
24.
Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate
systems: does geometry really matter? Pharm Res. 2009; 26: 235-43.
25.
Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, et al. Shape effects of
filaments versus spherical particles in flow and drug delivery. Nat Nano. 2007; 2: 249-55.
26.
Levick JR. Flow through interstitium and other fibrous matrices. Q J Exp Physiol.
1987; 72: 409-37.

37

27.
Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res.
1987; 47: 3039-51.
28.
Gullino PM, Grantham FH, Clark SH. The Collagen Content of Transplanted
Tumors. Cancer Research. 1962; 22: 1031-7.
29.
Krol A, Maresca J, Dewhirst MW, Yuan F. Available volume fraction of
macromolecules in the extravascular space of a fibrosarcoma: implications for drug
delivery. Cancer Res. 1999; 59: 4136-41.
30.
Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW. Mediating Tumor
Targeting Efficiency of Nanoparticles Through Design. Nano Letters. 2009; 9: 1909-15.
31.
Lieleg O, Baumgartel RM, Bausch AR. Selective filtering of particles by the
extracellular matrix: an electrostatic bandpass. Biophys J. 2009; 97: 1569-77.
32.
Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping
and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in
vitro. Biochem Pharmacol. 2003; 66: 1207-18.
33.
Vukovic V, Tannock IF. Influence of low pH on cytotoxicity of paclitaxel,
mitoxantrone and topotecan. Br J Cancer. 1997; 75: 1167-72.
34.
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev
Cancer. 2011; 11: 85-95.
35.
Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer.
2002; 2: 38-47.
36.
Krogh A. The anatomy and physiology of capillaries: Yale university press;
1922.
37.
Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, et al.
Quantum Dot-Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and
Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer. Nano
Letters. 2007; 7: 3065-70.
38.
Kang X, Cheng Z, Li C, Yang D, Shang M, Ma PÄ, et al. Core-Shell Structured
Up-Conversion Luminescent and Mesoporous NaYF4:Yb3+/Er3+@nSiO2@mSiO2
Nanospheres as Carriers for Drug Delivery. The Journal of Physical Chemistry C. 2011;
115: 15801-11.
39.
Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, et al. Drug Delivery with
Carbon Nanotubes for In vivo Cancer Treatment. Cancer Research. 2008; 68: 6652-60.

38

40.
Chen H, Moore T, Qi B, Colvin DC, Jelen EK, Hitchcock DA, et al. Monitoring
pH-Triggered Drug Release from Radioluminescent Nanocapsules with X-ray Excited
Optical Luminescence. ACS Nano. 2013; 7: 1178-87.
41.
Chu KS, Hasan W, Rawal S, Walsh MD, Enlow EM, Luft JC, et al. Plasma,
tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different
sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft.
Nanomedicine : nanotechnology, biology, and medicine. 2012.
42.
Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, et al.
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel
Nanoparticle with a Differentiated Pharmacological Profile. Science Translational
Medicine. 2012; 4: 128ra39.
43.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as
an emerging platform for cancer therapy. Nat Nano. 2007; 2: 751-60.
44.
Vaage J, Barberá-Guillem E, Abra R, Huang A, Working P. Tissue distribution
and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on
human prostate carcinoma xenografts. Cancer. 1994; 73: 1478-84.
45.
Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, et al. Selfassembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS
Nano. 2008; 2: 1696-702.
46.
Liu L, Xu K, Wang H, Tan PK, Fan W, Venkatraman SS, et al. Self-assembled
cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol. 2009;
4: 457-63.
47.
Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, et al. Formulation of
functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials.
2007; 28: 869-76.
48.
Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R.
Biodegradable long-circulating polymeric nanospheres. Science. 1994; 263: 1600-3.
49.
Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, et al.
Engineering of self-assembled nanoparticle platform for precisely controlled combination
drug therapy. Proc Natl Acad Sci U S A. 2010; 107: 17939-44.
50.
Kim SH, Tan JP, Fukushima K, Nederberg F, Yang YY, Waymouth RM, et al.
Thermoresponsive nanostructured polycarbonate block copolymers as biodegradable
therapeutic delivery carriers. Biomaterials. 2011; 32: 5505-14.

39

51.
Talelli M, Iman M, Varkouhi AK, Rijcken CJ, Schiffelers RM, Etrych T, et al.
Core-crosslinked polymeric micelles with controlled release of covalently entrapped
doxorubicin. Biomaterials. 2010; 31: 7797-804.
52.
Huang CK, Lo CL, Chen HH, Hsiue GH. Multifunctional Micelles for Cancer
Cell Targeting, Distribution Imaging, and Anticancer Drug Delivery. Advanced
Functional Materials. 2007; 17: 2291-7.
53.
Wu C, Bull B, Szymanski C, Christensen K, McNeill J. Multicolor Conjugated
Polymer Dots for Biological Fluorescence Imaging. ACS Nano. 2008; 2: 2415-23.
54.
Jin Y, Ye F, Zeigler M, Wu C, Chiu DT. Near-Infrared Fluorescent Dye-Doped
Semiconducting Polymer Dots. ACS Nano. 2011; 5: 1468-75.
55.
Wu C, Chiu DT. Highly Fluorescent Semiconducting Polymer Dots for Biology
and Medicine. Angewandte Chemie International Edition. 2013; 52: 3086-109.
56.
Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, et al. In vivo
evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control
Release. 2001; 72: 191-202.
57.
Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and
pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated
paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004; 10: 3708-16.
58.
Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, et al. Targeted
delivery of magnetic aerosol droplets to the lung. Nat Nano. 2007; 2: 495-9.
59.
Cole AJ, David AE, Wang J, Galbán CJ, Yang VC. Magnetic brain tumor
targeting and biodistribution of long-circulating PEG-modified, cross-linked starchcoated iron oxide nanoparticles. Biomaterials. 2011; 32: 6291-301.
60.
Heesakkers RA, Jager GJ, Hovels AM, de Hoop B, van den Bosch HC, Raat F, et
al. Prostate cancer: detection of lymph node metastases outside the routine surgical area
with ferumoxtran-10-enhanced MR imaging. Radiology. 2009; 251: 408-14.
61.
Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded
superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials.
2010; 31: 3694-706.
62.
Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/superparamagnetic iron
oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer
therapy. Biomaterials. 2011; 32: 7139-50.

40

63.
Kim D, Jeong YY, Jon S. A Drug-Loaded Aptamer-Gold Nanoparticle
Bioconjugate for Combined CT Imaging and Therapy of Prostate Cancer. ACS Nano.
2010; 4: 3689-96.
64.
Liu Z, Sun X, Nakayama-Ratchford N, Dai H. Supramolecular Chemistry on
Water-Soluble Carbon Nanotubes for Drug Loading and Delivery. ACS Nano. 2007; 1:
50-6.
65.
Welsher K, Liu Z, Sherlock SP, Robinson JT, Chen Z, Daranciang D, et al. A
route to brightly fluorescent carbon nanotubes for near-infrared imaging in mice. Nat
Nano. 2009; 4: 773-80.
66.
Welsher K, Sherlock SP, Dai H. Deep-tissue anatomical imaging of mice using
carbon nanotube fluorophores in the second near-infrared window. Proceedings of the
National Academy of Sciences. 2011; 108: 8943-8.
67.
Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancer targeting and
imaging with semiconductor quantum dots. Nat Biotech. 2004; 22: 969-76.
68.
Kim S, Lim C-K, Na J, Lee Y-D, Kim K, Choi K, et al. Conjugated polymer
nanoparticles for biomedical in vivo imaging. Chemical Communications. 2010; 46:
1617-9.
69.
Davis ME. Design and development of IT-101, a cyclodextrin-containing polymer
conjugate of camptothecin. Adv Drug Deliv Rev. 2009; 61: 1189-92.
70.
Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CH, Alabi CA, et al.
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and
tumor histological measurements. Proc Natl Acad Sci U S A. 2009; 106: 11394-9.
71.
Young C, Schluep T, Hwang J, Eliasof S. CRLX101 (formerly IT-101)-A Novel
Nanopharmaceutical of Camptothecin in Clinical Development. Curr Bioact Compd.
2011; 7: 8-14.
72.
Rapoport N, Nam K-H, Gupta R, Gao Z, Mohan P, Payne A, et al. Ultrasoundmediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized
perfluorocarbon nanoemulsions. Journal of Controlled Release. 2011; 153: 4-15.
73.
Al-Jamal WT, Kostarelos K. Liposomes: From a Clinically Established Drug
Delivery System to a Nanoparticle Platform for Theranostic Nanomedicine. Accounts of
Chemical Research. 2011; 44: 1094-104.

41

74.
Abraham SA, Edwards K, Karlsson Gr, MacIntosh S, Mayer LD, McKenzie C, et
al. Formation of transition metal-doxorubicin complexes inside liposomes. Biochimica et
Biophysica Acta (BBA) - Biomembranes. 2002; 1565: 41-54.
75.
Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally
MB, et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI:
Illustration of targeted delivery. Magnetic Resonance in Medicine. 2004; 51: 1153-62.
76.
Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, et al.
Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson
Med. 2006; 56: 1011-8.
77.
Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A New Temperaturesensitive Liposome for Use with Mild Hyperthermia: Characterization and Testing in a
Human Tumor Xenograft Model. Cancer Research. 2000; 60: 1197-201.
78.
Crossgrove J, Zheng W. Manganese toxicity upon overexposure. NMR in
Biomedicine. 2004; 17: 544-53.
79.
Parenti M, Rusconi L, Cappabianca V, Parati EA, Groppetti A. Role of dopamine
in manganese neurotoxicity. Brain Research. 1988; 473: 236-40.
80.
Lentschig MG, Reimer P, Rausch-Lentschig UL, Allkemper T, Oelerich M, Laub
G. Breath-hold gadolinium-enhanced MR angiography of the major vessels at 1.0 T:
dose-response findings and angiographic correlation. Radiology. 1998; 208: 353-7.
81.
Tagami T, Foltz WD, Ernsting MJ, Lee CM, Tannock IF, May JP, et al. MRI
monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a
multifunctional thermosensitive liposome. Biomaterials. 2011; 32: 6570-8.
82.
Diamond KR, Malysz PP, Hayward JE, Patterson MS. Quantification of
fluorophore concentration in vivo using two simple fluorescence-based measurement
techniques. J Biomed Opt. 2005; 10: 024007.
83.
Mourant JR, Johnson TM, Los G, Bigio IJ. Non-invasive measurement of
chemotherapy drug concentrations in tissue: preliminary demonstrations of in vivo
measurements. Phys Med Biol. 1999; 44: 1397-417.
84.
Palmer GM, Boruta RJ, Viglianti BL, Lan L, Spasojevic I, Dewhirst MW. Noninvasive monitoring of intra-tumor drug concentration and therapeutic response using
optical spectroscopy. J Control Release. 2010; 142: 457-64.

42

85.
Reif R, Wang M, Joshi S, A'Amar O, Bigio IJ. Optical method for real-time
monitoring of drug concentrations facilitates the development of novel methods for drug
delivery to brain tissue. J Biomed Opt. 2007; 12: 034036.
86.
Saager RB, Cuccia DJ, Saggese S, Kelly KM, Durkin AJ. Quantitative
fluorescence imaging of protoporphyrin IX through determination of tissue optical
properties in the spatial frequency domain. J Biomed Opt. 2011; 16: 126013.
87.
Koo H, Lee H, Lee S, Min KH, Kim MS, Lee DS, et al. In vivo tumor diagnosis
and photodynamic therapy via tumoral pH-responsive polymeric micelles. Chemical
Communications. 2010; 46: 5668-70.
88.
Tian G, Ren W, Yan L, Jian S, Gu Z, Zhou L, et al. Red-Emitting Upconverting
Nanoparticles for Photodynamic Therapy in Cancer Cells Under Near-Infrared
Excitation. Small. 2013; 9: 1929-38.
89.
Cunin F, Schmedake TA, Link JR, Li YY, Koh J, Bhatia SN, et al. Biomolecular
screening with encoded porous-silicon photonic crystals. Nat Mater. 2002; 1: 39-41.
90.
Wu EC, Andrew JS, Cheng L, Freeman WR, Pearson L, Sailor MJ. Real-time
monitoring of sustained drug release using the optical properties of porous silicon
photonic crystal particles. Biomaterials. 2011; 32: 1957-66.
91.
Doan VV, Sailor MJ. Luminescent Color Image Generation on Porous Silicon.
Science. 1992; 256: 1791-2.
92.
Park J-H, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ.
Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat
Mater. 2009; 8: 331-6.
93.
de Boer WDAM, TimmermanD, DohnalovaK, Yassievich IN, ZhangH, Buma
WJ, et al. Red spectral shift and enhanced quantum efficiency in phonon-free
photoluminescence from silicon nanocrystals. Nat Nano. 2010; 5: 878-84.
94.
Erogbogbo F, Yong K-T, Roy I, Hu R, Law W-C, Zhao W, et al. In Vivo
Targeted Cancer Imaging, Sentinel Lymph Node Mapping and Multi-Channel Imaging
with Biocompatible Silicon Nanocrystals. ACS Nano. 2010; 5: 413-23.
95.
Gu L, Park J-H, Duong KH, Ruoslahti E, Sailor MJ. Magnetic Luminescent
Porous Silicon Microparticles for Localized Delivery of Molecular Drug Payloads. Small.
2010; 6: 2546-52.

43

96.
Mik EG, Johannes T, Zuurbier CJ, Heinen A, Houben-Weerts JHPM, Balestra
GM, et al. In Vivo Mitochondrial Oxygen Tension Measured by a Delayed Fluorescence
Lifetime Technique. Biophysical Journal. 2008; 95: 3977-90.
97.
Jarvi MT, Niedre MJ, Patterson MS, Wilson BC. Singlet Oxygen Luminescence
Dosimetry (SOLD) for Photodynamic Therapy: Current Status, Challenges and Future
Prospects. Photochemistry and Photobiology. 2006; 82: 1198-210.
98.
Niedre MJ, Yu CS, Patterson MS, Wilson BC. Singlet oxygen luminescence as an
in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical
amino-levulinic acid. Br J Cancer. 2005; 92: 298-304.
99.
Cheong WF, Prahl SA, Welch AJ. A review of the optical properties of biological
tissues. Quantum Electronics, IEEE Journal of. 1990; 26: 2166-85. doi:10.1109/3.64354.
100. Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dotmucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. Journal of
Controlled Release. 2011; 153: 16-22.
101. Hampl J, Hall M, Mufti NA, Yao Y-mM, MacQueen DB, Wright WH, et al.
Upconverting Phosphor Reporters in Immunochromatographic Assays. Analytical
Biochemistry. 2001; 288: 176-87.
102. Ukonaho T, Rantanen T, Jämsen L, Kuningas K, Päkkilä H, Lövgren T, et al.
Comparison of infrared-excited up-converting phosphors and europium nanoparticles as
labels in a two-site immunoassay. Analytica Chimica Acta. 2007; 596: 106-15.
103. Petoral RM, Söderlind F, Klasson A, Suska A, Fortin MA, Abrikossova N, et al.
Synthesis and Characterization of Tb3+-Doped Gd2O3 Nanocrystals: A Bifunctional
Material with Combined Fluorescent Labeling and MRI Contrast Agent Properties. The
Journal of Physical Chemistry C. 2009; 113: 6913-20.
104. Mader HS, Kele P, Saleh SM, Wolfbeis OS. Upconverting luminescent
nanoparticles for use in bioconjugation and bioimaging. Current Opinion in Chemical
Biology. 2010; 14: 582-96.
105. Yang J, Sandoval S, Alfaro JG, Aschemeyer S, Liberman A, Martin DT, et al.
Red-luminescent europium (III) doped silica nanoshells: synthesis, characterization, and
their interaction with HeLa cells. J Biomed Opt. 2011; 16: 066012.
106. Xu Z, Gao Y, Huang S, Ma P, Lin J, Fang J. A luminescent and mesoporous coreshell structured Gd2O3 : Eu(3+)@nSiO2@mSiO2 nanocomposite as a drug carrier.
Dalton transactions (Cambridge, England : 2003). 2011; 40: 4846-54.

44

107. Capozzi V, Perna G, Carmone P, Gallone A, Lastella M, Mezzenga E, et al.
Optical and photoelectronic properties of melanin. Thin Solid Films. 2006; 511‚Äì512:
362-6.
108. Nordlung JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne JP. The
Physical Properties of Melanins. In: Sarna T, Swartz HA, editors. The Pigmentary
System: Physiology and Pathophysiology. 2nd Edition ed; 1998. p. 311-41.
109. Ortonne JP. Photoprotective properties of skin melanin. British Journal of
Dermatology. 2002; 146: 7-10.
110. de Gruijl FR, van Kranen HJ, Mullenders LHF. UV-induced DNA damage,
repair, mutations and oncogenic pathways in skin cancer. Journal of Photochemistry and
Photobiology B: Biology. 2001; 63: 19-27.
111. Stolik S, Delgado JA, Pérez A, Anasagasti L. Measurement of the penetration
depths of red and near infrared light in human "ex vivo" tissues. Journal of
Photochemistry and Photobiology B: Biology. 2000; 57: 90-3.
112. Chen G, Shen J, Ohulchanskyy TY, Patel NJ, Kutikov A, Li Z, et al. (αNaYbF4:Tm3+)/CaF2 Core/Shell Nanoparticles with Efficient Near-Infrared to NearInfrared Upconversion for High-Contrast Deep Tissue Bioimaging. ACS Nano. 2012; 6:
8280-7.
113. Gai S, Yang P, Li C, Wang W, Dai Y, Niu N, et al. Synthesis of Magnetic, UpConversion Luminescent, and Mesoporous Core–Shell-Structured Nanocomposites as
Drug Carriers. Advanced Functional Materials. 2010; 20: 1166-72.
114. Chen H, Colvin DC, Qi B, Moore T, He J, Mefford OT, et al. Magnetic and
optical properties of multifunctional core-shell radioluminescence nanoparticles. Journal
of Materials Chemistry. 2012; 22: 12802-9.
115. Sun C, Pratx G, Carpenter CM, Liu H, Cheng Z, Gambhir SS, et al. Synthesis and
Radioluminescence of PEGylated Eu3+-doped Nanophosphors as Bioimaging Probes.
Advanced Materials. 2011; 23: H195-H9.
116. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proceedings
of the National Academy of Sciences of the United States of America. 2006; 103: 4930-4.
117. Huang X, Li L, Liu T, Hao N, Liu H, Chen D, et al. The shape effect of
mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in
vivo. ACS Nano. 2011; 5: 5390-9.

45

118. Ntziachristos V. Going deeper than microscopy: the optical imaging frontier in
biology. Nature Methods. 2010; 7: 603+.
119. Xu CT, Svenmarker P, Liu H, Wu X, Messing ME, Wallenberg LR, et al. HighResolution Fluorescence Diffuse Optical Tomography Developed with Nonlinear
Upconverting Nanoparticles. ACS Nano. 2012; 6: 4788-95.
120. Carpenter CM, Sun C, Pratx G, Rao R, Xing L. Hybrid x-ray/optical
luminescence imaging: characterization of experimental conditions. Med Phys. 2010; 37:
4011-8.
121. Carpenter CM, Pratx G, Sun C, Xing L. Limited-angle x-ray luminescence
tomography: methodology and feasibility study. Physics in Medicine and Biology. 2011;
56: 3487.
122. Chen D, Zhu S, Yi H, Zhang X, Chen D, Liang J, et al. Cone beam x-ray
luminescence computed tomography: A feasibility study. Medical Physics. 2013; 40:
031111-14.
123. Hardman R. A toxicologic review of quantum dots: toxicity depends on
physicochemical and environmental factors. Environ Health Perspect. 2006; 114: 165-72.
124. Derfus AM, Chan WCW, Bhatia SN. Probing the Cytotoxicity of Semiconductor
Quantum Dots. Nano Letters. 2003; 4: 11-8.
125. Cobley CM, Chen J, Cho EC, Wang LV, Xia Y. Gold nanostructures: a class of
multifunctional materials for biomedical applications. Chemical Society Reviews. 2011;
40: 44-56.
126. E. Abraham Peter B. Himmel GUY. Management of Rheumatoid Arthritis:
Rationale for the Use of Colloidal Metallic Gold. Journal of Nutritional and
Environmental Medicine. 1997; 7: 295-305.
127. Hart FD, Lewis-Faning E, Council RS-cotER. Gold Therapy in Rheumatoid
Arthritis: Final Report of a Multicentre Controlled Trial. Ann Rheum Dis; 1961. p. 31534.
128. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photo-thermal tumor
ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004; 209:
171-6.
129. Schwartz JA, Shetty AM, Price RE, Stafford RJ, Wang JC, Uthamanthil RK, et al.
Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine
model. Cancer Res. 2009; 69: 1659-67.

46

130. Schwartz JA, Price RE, Gill-Sharp KL, Sang KL, Khorchani J, Goodwin BS, et
al. Selective nanoparticle-directed ablation of the canine prostate. Lasers Surg Med.
2011; 43: 213-20.
131. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Gannon WE, Walker M, et
al. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal
Gold-rhTNF Nanomedicine. Clinical Cancer Research. 2010; 16: 6139-49.
132. Stroh A, Zimmer C, Gutzeit C, Jakstadt M, Marschinke F, Jung T, et al. Iron
oxide particles for molecular magnetic resonance imaging cause transient oxidative stress
in rat macrophages. Free Radic Biol Med. 2004; 36: 976-84.
133. Bourrinet P, Bengele HH, Bonnemain B, Dencausse A, Idee JM, Jacobs PM, et al.
Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall
superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol. 2006;
41: 313-24.
134. Sharma R, Saini S, Ros PR, Hahn PF, Small WC, de Lange EE, et al. Safety
profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial
data. J Magn Reson Imaging. 1999; 9: 291-4.
135. Kostarelos K, Bianco A, Prato M. Promises, facts and challenges for carbon
nanotubes in imaging and therapeutics. Nat Nano. 2009; 4: 627-33.
136. Poland CA, Duffin R, Kinloch I, Maynard A, Wallace WAH, Seaton A, et al.
Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like
pathogenicity in a pilot study. Nat Nano. 2008; 3: 423-8.
137. Schipper ML, Nakayama-Ratchford N, Davis CR, Wong Shi Kam N, Chu P,
Zhuang L, et al. A pilot toxicology study of single-walled carbon nanotubes in a small
sample of mice. Nature Nanotechnology. 2008; 3: 216-21.
138. Bai Y, Zhang Y, Zhang J, Mu Q, Zhang W, Butch ER, et al. Repeated
administrations of carbon nanotubes in male mice cause reversible testis damage without
affecting fertility. Nat Nanotechnol. 2010; 5: 683-9.
139. Lacerda L, Ali-Boucetta H, Herrero MA, Pastorin G, Bianco A, Prato M, et al.
Tissue histology and physiology following intravenous administration of different types
of functionalized multiwalled carbon nanotubes. Nanomedicine (Lond). 2008; 3: 149-61.
140. Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp Cd, Prato M, et al. Tissue
biodistribution and blood clearance rates of intravenously administered carbon nanotube
radiotracers. Proceedings of the National Academy of Sciences of the United States of
America. 2006; 103: 3357-62.

47

141. Murray AR, Kisin ER, Tkach AV, Yanamala N, Mercer R, Young SH, et al.
Factoring-in agglomeration of carbon nanotubes and nanofibers for better prediction of
their toxicity versus asbestos. Part Fibre Toxicol. 2012; 9: 10.
142. Tang ACL, Hwang G-L, Tsai S-J, Chang M-Y, Tang ZCW, Tsai M-D, et al.
Biosafety of Non-Surface Modified Carbon Nanocapsules as a Potential Alternative to
Carbon Nanotubes for Drug Delivery Purposes. PLoS ONE. 2012; 7: e32893.
143. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold Nanoparticles
Are Taken Up by Human Cells but Do Not Cause Acute Cytotoxicity. Small. 2005; 1:
325-7.
144. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, et
al. PEG-modified gold nanorods with a stealth character for in vivo applications. J
Control Release. 2006; 114: 343-7.
145. Hale GM, Querry MR. Optical Constants of Water in the 200-nm to 200-µm
Wavelength Region. Appl Opt. 1973; 12: 555-63.
146. Lim YT, Kim S, Nakayama A, Stott NE, Bawendi MG, Frangioni JV. Selection
of quantum dot wavelengths for biomedical assays and imaging. Molecular Imaging.
2003; 2: 50-64.
147. Smith AM, Mancini MC, Nie S. Bioimaging: Second window for in vivo
imaging. Nat Nano. 2009; 4: 710-1.
148. Won N, Jeong S, Kim K, Kwag J, Park J, Kim SG, et al. Imaging depths of nearinfrared quantum dots in first and second optical windows. Molecular Imaging. 2012; 11:
338-52.
149.

Weissleder R. A clearer vision for in vivo imaging. Nat Biotech. 2001; 19: 316-7.

150. Gerd M, Joel SK. Positron emission tomography. Physics in Medicine and
Biology. 2006; 51: R117.
151. Li Z, Conti PS. Radiopharmaceutical chemistry for positron emission
tomography. Advanced Drug Delivery Reviews. 2010; 62: 1031-51.

48

CHAPTER TWO
MULTIFUNCTIONAL NANOPARTICLES TO IMPROVE THE SAFETY OF DRUG
DELIVERY
Current challenges in chemotherapy include the non-ideal biodistribution of
drugs, limited dose due to systemic toxicity, and excessive dosing regimen required
because of rapid drug clearance. These challenges can be overcome with nano-sized drug
delivery vehicles capable of prolonging drug release, increasing circulation time, and
localizing delivery at the site of interest. However, hesitance to employ nanomaterials for
medical applications often stems from concerns regarding nanomaterial toxicity. Though
some nanoparticle (NP) formulations have successfully reached clinical use, significant
NP toxicity persists. This may generally be attributed to choice of nanomaterial,
degradation, size, shape, and in vivo stability. Using carbon nanotubes as a proof-ofconcept, we show that coating inorganic nanoparticles with a multifunctional,
amphiphilic polymer coating comprised of poly(lactide)-poly(ethylene glycol) (PLAPEG) decreases NP toxicity in vitro and in vivo. Moreover, such a coating enables the
controlled delivery of the anticancer drug paclitaxel (PTX).

2.1. Methods to Coat Inorganic Nanoparticles
Inorganic NP are often unsuitable for drug delivery applications due to their
propensity for aggregation and difficulty in sustaining drug release. However, coating
inorganic NP with polymer may improve their suitability for drug delivery applications.
Carbon nanotubes (CNTs), nano-hydroxyapatite (nHA), nano-graphene sheets (nGr), and
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europium-doped gadolinium sulfoxide (Gd2O2S:Eu) radioluminescent nanoparticles were
coated with amphiphilic, biodegradable polymers. Here we will focus on CNTs as a
proof-of-concept to show that inorganic nanoparticles may be coated with polymer to
improve drug delivery and decrease nanotoxicity.
Recent research indicates the utility of carbon nanotubes as drug delivery vehicles
[1-7]. In cancer nanomedicine, carbon nanotubes are currently investigated for their
ability to act as drug delivery vehicles, mediators for hyperthermia, or act as imaging
agents because they can be easily internalized into cells [2, 3, 5, 8-10]. Though the large
specific surface area of CNTs provides the potential for delivering high drug doses,
pristine CNTs are limited in their applications as drug delivery vehicles because their
hydrophobicity causes aggregation and toxicity [11-16].
Most approaches for CNT drug loading utilize adsorption or covalent conjugation
of drugs on the surface of CNTs [2, 17]. Hongjie Dai’s group has developed a drug
delivery system whereby a phospholipid-PEG molecule is adsorbed onto the CNT surface
[2, 3, 18, 19]. Here, tumor targeting moieties or modified drugs may be either chemically
conjugated to the PEG chain ends, or drugs may be adsorbed (doxorubicin) onto the
nanotube surface due to pi-stacking of benzene rings. Previously, Pastorin et al. [20]
directly functionalized the sidewall of CNTs with methotrexate, an anti-cancer drug, via
1,3-dipolar cycloaddition. Surface adsorption or conjugation is controlled by the available
CNT surface functional groups and reactivity, however this reduces the availability of
functional groups for further attachment of PEG or targeting ligands.
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Table 2.1 Experimental plans to test effect of polymer coating on toxicity and drug
delivery
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Moreover, the surface properties and pharmacokinetics of the CNT is expected to change
with surface adsorbed drugs, drugs conjugated to the surface, or drugs conjugated to PEG
chain ends [3, 21]. In a study of CNTs functionalized with PEG-PTX, the conjugation of
PTX to the PEG molecule decreased the circulation half-life of CNT-PEG from 3.3 hr to
1.1 hr for CNT-PEG-PTX. Here we describe an amphiphilic copolymer, PLA-PEG,
which functionalizes the CNT surface. In this system, hydrophobic PLA acts as a
reservoir to sequester hydrophobic drugs and mediate their release, while hydrophilic
PEG stabilizes CNTs to reduce aggregation in an aqueous solution. While current CNTbased therapies for drug delivery and imaging have shown encouraging results, the
translational success of this system is expected to be facilitated by preventing aggregation
due to surface properties, and improving drug loading to increase therapeutic efficacy.

2.2.1. Synthesis of Coated Nanoparticles
Nanomaterials were covalently coated with PLA using a room temperature, ringopening polymerization. In a typical reaction, 40 mg of MWCNT-OH (Sun Innovations,
Fremont, CA, USA) and varying amounts of d,l lactide (Purac Biomaterials,
Lincolnshire, IL, USA) were dissolved in 4 ml of acetonitrile. Phosphazene base P2-t-Bu
at 2M in tetrahydrofuran (Sigma-Aldrich) was added as a catalyst. This reaction resulted
in CNT coated with PLA (CL). Next, methoxy-PEG-isocyanate (Nanocs Inc, New York,
NY, USA) was dissolved in 2 ml of solvent and added directly to the reaction mixture.
The reaction then proceeded under nitrogen and was washed via centrifugation. The
product, CNT coated with PLA-PEG (CLP), was lyophilized and stored at -20 °C under
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nitrogen. This reaction scheme could be followed using a number of inorganic
nanoparticle templates. To characterize nanomaterials, NMR was performed with a
Bruker Avance 300, and ATR FT-IR was performed with a Thermo-Nicolet Magna 550
equipped with a Thermo-SpectraTech Foundation series Endurance Diamond ATR. 1HNMR (300 MHz, CDCl3, δ): 7.26 (s, CDCl3), 5.17 (q, -C(=O)-CH(CH3)-), 3.65 (s, CH2CH2-O-), 1.59 (d, -CH(CH3)-); IR 2881 cm-1 (-CH2-CH2-O-), 1745 cm-1 (C=O).
Thermogravimetric analysis was performed on a TA Instruments Hi-Res TGA 2950
thermogravimetric analyzer under nitrogen from 25 °C to 600 °C at 20 °C/min.
Transmission electron microscope images were taken on a Hitachi HD2000 at 200 kV.

2.2.2. Cell Culture
Human umbilical vein endothelial cells (Lonza, Walkersville, MD, USA) were
grown on collagen-1 coated flasks (Thermo Scientific, Rockford, IL, USA) in endothelial
growth media (Lonza, Walkersville, MD, USA). U-87 glioblastoma cells (American
Type Culture Collection, Manassas, VA, USA) were grown on CellBind-treated flasks
(Corning, Tewksbury, MA, USA) in EMEM (American Type Culture Collection)
supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA,
USA). Cells were subcultured at 37°C and 5% CO2. Rat lung epithelial cells RLE-6TN
(American Type Culture Collection) were grown in Ham’s F12 medium with 2 mM Lglutamine supplemented with 0.01 mg/ml bovine pituitary extract, 0.005 mg/ml insulin,
2.5 ng/ml insulin-like growth factor, 0.00125 mg/ml transferrin, 2.5 ng/ml epidermal
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growth factor, 1000 U/ml penicillin-G, 100 µg/ml streptomycin, and 10% fetal bovine
serum.
2.2.3. CNT-PLA-PEG Uptake In Vitro
CLP uptake in HUVEC and U-87 cells was determined via confocal microscopy.
Cells were seeded at 12,00 cells per chamber in a Lab-Tek 8-chambered slide (Thermo
Scientific). Nanoparticles were loaded with Alexa Fluor 647 cadaverine (Life
Technologies, Grand Island, NY, USA), a fluorescent dye, by dissolving Alexa Fluor 647
(AF647) in a 50/50 dimethylformamide/acetonitrile (DMF/ACN) solution. CLP was
dissolved in the AF647 solution on a rotisserie. Next, fluorescent dye-loaded CLP
solution was prepared by solvent evaporation in HyPure water (Thermo Scientific).
Samples were washed via centrifugation twice in HyPure water and once in sterile
phosphate buffered saline (Sigma-Aldrich). Samples were re-suspended at 0.25 mg/ml in
cell culture media and added to cells. After 24 hours, media was removed and cells were
washed twice with sterile phosphate buffered saline (PBS). Cells were fixed with a 4%
formaldehyde solution in PBS for 30 minutes, and then washed with PBS. Cells were
incubated with a 0.1% Triton-X solution for 2 minutes, washed with PBS, and stained
with Alexa Fluor 488 phalloidin. Finally, cells were mounted with VectaShield
fluorescent mounting medium containing DAPI (Vector Laboratories, Burlingame, CA,
USA). Slide chambers were removed and the slide was cover slipped. Confocal
microscope images were taken with a Nikon Eclipse Ti confocal microscope.
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2.2.4. Paclitaxel Release from CNT-PLA-PEG
Release of PTX from CLP was measured using high performance liquid
chromatography (HPLC). Paclitaxel (LC Laboratories, Woburn, MA, USA) was
encapsulated by dissolving CLP and PTX in ACN and rotating on a rotisserie protected
from light. The CLP/PTX solution was then dropped in HyPure deionized water and PTX
was encapsulated via solvent evaporation. Samples were washed three times in HyPure
water via centrifugation. CLP/PTX was re-dispersed in HyPure water and added to the
top of a 3.5 kD Slide-a-Lyzer MINI dialysis unit (Thermo Scientific). Each dialysis unit
was placed in a vial with HyPure deionized water. Five repeats were used in this release
study and samples were placed in an incubator at 37°C and 5% CO2 for the duration of
the study. At each time point dialysate was removed and frozen, and fresh HyPure water
was replaced. Lyophilized aliquots were analyzed via HPLC on a Waters 1525 Binary
HPLC pump with a 2998 photodiode array detector. An Alltima C18 column (Grace,
Deerfield, IL, USA) was used with dimensions 4.6 x 25 mm with 5 µm pores. Samples
and standards were dissolved in acetonitrile. The mobile phase used was 60% acetonitrile
and 40% water. The mobile phase flow rate was 1 ml/min and PTX was detected at a
wavelength of 227 nm with an average elution time of 11.5 minutes.

2.2.5. In Vitro Inflammation and Toxicity Studies
RLE-6TN cells were plated at 100,000 cells per well in a 12-well plate (Corning)
and incubated at 37 °C and 5% CO2 for 24 hours. Media was exchanged and returned to
temperature before being dosed with NP at 1 or 10 µg/cm2 for 6 hr. Media was then
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removed and cells were lysed by Trizol (Life Technologies) and stored at -80°C. RNA
was extracted using RNeasy mini kit (Qiagen, Valencia, CA, USA) and quantitated on a
Nanodrop (Thermo Scientific). Reverse transcription of 1 µg of RNA was performed
using a QuantiTect reverse transcription kit (Qiagen). QuantiTect primer assays (Qiagen)
and SYBR green master mix (Qiagen) were utilized for Quantitative real-time PCR to
examine mRNA expression levels of IL1rl1, IL-6, ICAM1 in RLE cells. Cycle threshold
(Ct) values and internal reference cDNA levels for the target genes were determined by
an Applied Biosystems StepOnePlus Real-Time PCR System (ABI). The cDNA levels of
each treatment were then normalized to GAPDH, used as an internal reference, by the
equation Cttarget- Ctgapdh. The relative expression of each target was then calculated by 2[ΔΔCt]

, where ΔΔCt is defined as ΔCttreatment - ΔCtcontrol.
HUVEC and U-87 cells were seeded at 10,000 cells per well in a 96-well plate

(Corning) with five repeats per test concentration. CNT and CLP were prepared by
solvent evaporation in HyPure water. Solutions were stirred for 2 hours and washed by
centrifugation. NP were then re-dispersed in media and added to cells at different
concentrations. Cells were incubated with the NP for 24 hours at 37°C and 5% CO2.
Next, NP media was removed and cells were gently washed twice with PBS. A Presto
Blue cell viability assay (Life Technologies) was performed by mixing Presto Blue
reagent at a 1:9 ratio with cell culture media. 100 µl of working solution was added to the
cells and incubated protected from light for 45 minutes at 37°C and 5% CO2. Fluorescent
intensity was measured with a BioTek Synergy 4 plate reader at an excitation wavelength
of 560 nm and emission wavelength of 590 nm. Cell viability was determined by
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normalizing fluorescent intensity to the average intensity of five wells of cells only
treated with media.
For Live/Dead staining, U-138 human glioblastoma cells were seeded at 10,000
cells/chamber in an 8-chambered slide and allowed to attach overnight. The next day nGr
and PLA-PEG coated nGr (nGrLP) were dispersed in cell culture media and added to
cells at varying concentrations. Cells were incubated with nanomaterials for 24 hours and
then washed gently with sterile phosphate buffered saline. Live/Dead working solution
was made by diluting ethidium homodimer-1 (EthD-1) and calcein AM to final
concentrations of 2 nM and 1 nM, respectively, in Dulbecco’s PBS. One control well was
killed by treating with 70% ethanol for 1 minute. Working solution was added to cells
and incubated for 30 minutes. Cells were washed with PBS, fixed with 4% formaldehyde
for 30 minutes, and coverslipped. Widefield fluorescent images were taken on a Nikon
Eclipse Ti.
Efficacy studies of PTX-loaded CLP were performed using U-87 cells, in which
cells were seeded at 10,000 cells per well in a 96-well plate. CLP was loaded with PTX
as previously described and CLP/PTX was added to cells at 2.5, 5, and 10 µg/cm2.
Estimated PTX concentrations, based upon the release data were 70, 140, and 280 nM,
respectively. Cells were incubated for 6 hours or 24 hours, and washed twice with sterile
PBS. Fresh media was added to cells and they were grown for a total of 72 hours after
initial exposure to NP. Cell viability was measured with a Presto Blue assay.
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2.2.6. In Vivo Biodistribution Studies
Animals were housed at Clemson University’s Godley-Snell Research Center or
within the Department of Comparative Medicine at East Carolina University. All studies
were done in accordance with Clemson and East Carolina University Institutional Animal
Care and Use Committee (IACUC) approved protocols. For the CNT biodistribution
studies, Balb/c mice were used and no tumor xenografts were implanted. CL or CLP was
loaded with AF 647 as previously described. The final wash in the centrifugal filter unit
was done in sterile PBS. Samples were re-dispersed at 1 mg/ml in sterile PBS, and 200 µl
of NP was administered via a tail vein injection. Live animal imaging was done with an
IVIS Lumina XR small animal imaging system. At the final time point of 24 hours,
animals were euthanized and kidney, liver, spleen, muscle, fat, heart, lung, and brain
tissue was retrieved. Tissues were fixed in 4% formaldehyde and stored protected from
light at 4 °C. For tissue staining, organs were incubated overnight in a 30% sucrose in
PBS solution. Next, samples were embedded in optimal cutting temperature (O.C.T.)
compound (Sakura, Torrance, CA, USA) and sectioned at 10 µm on a Microm HM 505N
cryostat microtome. Sections were then stained with haematoxylin and eosin. Histology
images were taken on a Nikon Labopho-2 microscope with a Sony HDR-HC9 camera.
Tumor xenograft biodistribution studies were performed to observe differences
between CLP and nGrLP. U-138 cells were washed with sterile PBS. Cells were
collected and concentrated in serum-free media at 40,000,000 cells/ml. 100 µl of cell
suspension was added to 100 µl of matrigel. Athymic nude Balb/c mice were anesthetized
with ketamine-xylazine. Skin was disinfected with chlorohexidine and eyes were
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lubricated with Puralube ophthalmic ointment. A 1 cm sagittal incision was made across
the top of the skull. The skull was sterilized with hydrogen peroxide. A hole was made 2
mm anterior and 1 mm lateral of the bregma using a 25-gauge needle. 3 µl of
cell/matrigel solution was injected ~3 mm deep into the brain over 1 min. The skull was
closed using dental cement and the incision site was stapled shut. Tumors were allowed
to grow for 10 days. After 10 days, biodistribution studies were performed. nGrLP or
CLP was prepared via previously described fluorescent loading method. Samples were
washed in sterile HyPure H2O and re-dispersed in sterile PBS at 1 mg/ml. 200 µl of NP
was administered via a tail vein injection. Animals were euthanized at 24 hours and
fluorescent images were taken with an IVIS Lumina XR small animal imaging system.
Saline was injected as a control.

2.2.7. In Vivo Inflammatory Response and Maximum Tolerated Dose
C57BL/6 mice were obtained from Jackson Labs at 4 weeks of age. Mice were
instilled with 4 mg/kg of CNT or CLP by oropharyngeal aspiration, and euthanized 30
days following aspiration of CNT or CLP. Mouse lungs underwent in situ
bronchoalveolar lavage (BAL). The right lung was lavaged 4 times (26.25 ml/kg body
weight) with ice-cold Hank’s balanced salt solution (HBSS). Bronchoalveolar lavage
fluid (BALF) was collected and centrifuged at 1000 g for 10 min at 4 °C. Cell pellets
were re-suspended in 1 ml HBSS and counted. In order to obtain differential cell counts,
20,000 cells from each BALF sample were centrifuged using a Cytospin IV (Shandon
Scientific Ltd, Cheshire, UK) and stained with a three-step hematology stain (Richard
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Allan Scientific, Kalamazoo, MI). Cell differential counts were determined and imaged
for presence of CNTs or CLPs. Left lungs from CNT or CLP treated mice were perfused
with 10% neutral buffered formalin fixative and stored for 24 h, then processed and
embedded in paraffin. Samples were then sectioned at a thickness of 5 µM and were
mounted on slides for staining with Masson’s trichrome to detect morphological changes
and collagen deposition.
For the maximum tolerated dose studies, NPs were prepared as previously
described. After washing, NPs were re-dispersed in sterile PBS at concentrations
determined by mouse body mass. NP solutions were sonicated just prior to injection due
to rapid aggregation of pristine CNTs. Following injection mice were monitored for 6
hours for signs of distress or deteriorating conditions. Mouse body mass and food
consumption was monitored every day for one week following injection. Subjects whose
body mass went below 20% of initial body mass or who were non-responsive were
euthanized immediately. All subjects were euthanized at the final time point per IACUC
protocol requirements.

2.2. Results and Discussion
2.2.1. Preparation and Characterization of Coated NP
The CLP drug delivery system was synthesized by using non-toxic organocatalyst
phosphazene base P2-t-Bu. We eliminated the need for high temperature polymerization
methods and potential toxicity from tin-based catalysts [22-24]. PLA was grafted on the
surface of hydroxyl-functionalized MWCNT with an inner diameter of 5-15 nm, outer
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diameter of 30-50 nm, and lengths from 10-20 µm. CNTs were used as provided and
were dissolved in the presence of d,l lactide in anhydrous acetonitrile. CL particles were
PEGylated by adding methoxy-PEG5k-isocyanate directly into the reaction. Our rationale
for this approach was to utilize the high reactivity of isocyanate groups to chemically cap
PLA with the PEG molecule on the surface of CNTs without using a purification step
[25-27]. The CLP particles were washed through centrifugation to remove residual
monomer, PEG, and catalyst, and the amount of polymeric coating was quantified by
thermogravimetric analysis under N2 flow (Figure 2.1A).
Pristine CNT showed no decomposition over the entire temperature range, from
30 °C to 600 °C, whereas CL exhibited a single stage of decomposition around 280 °C,
revealing that approximately 60 wt.% of CL was the polymer PLA. CLP samples showed
a two-stage decomposition, with PLA decomposing at approximately 280 °C and PEG
decomposing at approximately 430 °C. This two-stage decomposition indicates the
presence of two polymers: approximately 60 wt.% PLA and 20 wt.% PEG. The chemical
bonds in the CNT composites were characterized via Fourier transform infrared
spectroscopy (Figure 2.1B). The carbonyl stretch peak at 1745 cm-1, present in both the
CL and CLP samples, corresponds to the ester bond present in PLA. In the CLP sample
there is a peak at 2881 cm-1, which corresponds to the ether bond in PEG (Figure 2.1B,
inset). 1H NMR was taken on a Bruker Avance 300 NMR (300 MHz, CDCl3) for CL
(Figure 2.1C) and CLP (Figure 2.1D). Peaks for PLA were observed at 1.59 and 5.17
ppm. PEG had a single peak at 3.65 ppm. This data indicates the successful coating of
CNT with an inner layer of PLA and an outer layer of PEG. Transmission electron
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microscope images of CNT (Figure 2.1E) and CLP (Figure 2.1F) show that the polymer
coating was approximately 10-15 nm.
Successful synthesis of nGrLP using the one-pot room temperature approach was
also successful. PLA was grafted on the surface of hydroxyl-functionalized nGr. PLA
coated nGr (nGrL) was PEGylated by introducing mPEG-isc directly into the reaction
mixture. Polymer coating on nGr was confirmed via TGA, TEM, and NMR (Figure 2.2).
Uncoated nGr showed little decomposition (~5 wt%) across the temperature range of 20
°C to 600 °C, while nGrL showed decomposition of approximately 20 wt% at 280 °C.
PEG was shown to decompose around 430 °C. Thus, nGrLP was coated with
approximately 20 wt% PLA and 70 wt% mPEG. TEM showed qualitative surface
differences between nGr and nGrLP (Figure 2.2B), and nGr was plate shaped with
dimensions of 5 µm by 5 µm. NMR confirmed the presence of PLA (Figure 2.2C) and
PLA-PEG (Figure 2.2D).
Thus, this approach provides a means for covalently functionalizing inorganic NP
with a multifunctional, polymeric coating. Our rationale was to encapsulate hydrophobic
drug within the hydrophobic PLA matrix, which would then mediate the drug’s
controlled release. The PEG layer is intended improve the aqueous dispersion of the
nanomaterials, reduce NP clearance, and mediate the interaction of the NP with the body.
Since PLA and PEG are FDA-approved polymers, we expected the polymers to decrease
toxicity associated with the inorganic NP.

62

Figure 2.1 Chemical characterization of coated CNTs. (A) Thermogravimetric analysis
(TGA) of CNT, CNT-PLA (CL), and CNT-PLA-PEG (CLP) showing the percent of
polymer coating. (B) FTIR spectra of coated particles with expanded view to show the
corresponding peaks for PEG at 2881 cm-1 (inset). (C,D) 1H NMR spectra for CL and
CLP, with an inset of the polymer structure for PLA-PEG. (E,F) TEM images of CNT
and CLP. CLP shows a 10-15 nm thick polymer coating. Scale bars represent 150 nm.
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Figure 2.2 Chemical characterization of coated nGr. (A) Thermogravimetric analysis of
nGr, nGr-PLA (nGL), and nGr-PLA-PEG (nGrLP) confirmed polymer coating. (B)
Transmission electron microscopy of nGr and nGrLP showed qualitative, superficial
differences between the two samples. Scale bars represent 500 nm. Nuclear magnetic
resonance spectroscopy of (C) nGrL and (D) nGrLP confirmed the structure of polymer
coated on nGr.
2.2.2. In Vitro Uptake, Toxicity, Inflammatory Response, and Controlled Release
CNTs were coated with PLA and PEG, two FDA-approved polymers, to decrease
toxicity. The rationale is based on controlling the surface properties of CNTs, allowing
them to disperse in an aqueous solution and allowing the polymer to mediate the
interactions of carbon nanomaterials with cells. By improving aqueous dispersion, the
interaction of CNT with cells is reduced and aggregation of the nanoparticles in blood is
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subsequently reduced. Nanoparticles loaded with a hydrophobic fluorescent dye (Alexa
Fluor 647) were used to study the uptake of CLP in two different cell lines: U-87 human
glioblastoma cells and human umbilical vein endothelial cells (HUVEC) as a control.
Cells were incubated with dye-loaded CLP for 24 hr in a chambered glass slide. Cells
were washed, fixed, and stained for actin filaments and nuclei. Figure 2.3A and Figure
2.3B show the confocal images of the uptake of CLP in HUVEC and U-87 cells,
respectively.
Toxicity in both HUVEC and U-87 cell lines was measured with a Presto Blue
cell viability assay in which metabolically active cells reduced the non-fluorescent
resazurin in the Presto Blue working solution into a red-fluorescent resorufin [28]. Cells
were treated with varying concentrations of pristine CNT or CLP, and percent cell
viability was determined by normalizing the fluorescent intensity of each test group with
the average intensity of cells receiving only media. CNT showed a dose dependent
toxicity in both HUVEC (Figure 2.3C) and U-87 (Figure 2.3D) cell lines. A Student’s ttest (p-value < 0.05) was performed to compare toxicity between CNT and CLP at each
concentration. CNTs were significantly more toxic than CLP in HUVEC cells at all
concentrations, up to 700 µg/cm2. U-87 cells exhibited similar results where CNTs were
significantly more toxic than CLP, from 140 µg/cm2 to 700 µg/cm2. Moreover, Tukey’s
Honestly Significant Difference (HSD) test determined a demonstrable significance
between each concentration of CNT and the 0 nM concentration (cell control). Though
pristine CNT was significantly toxic in both HUVEC and U-87 cell lines in
concentrations of approximately 70 µg/cm2, no significant toxicity was evident in CLP
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using concentrations 10 times higher than pristine. Thus, coating our samples with the
biocompatible PLA-PEG polymer reduces the toxicity associated with CNTs in vitro,
which is critical for medical applications.
Inflammatory responses to CNT and CLP were tested in rat lung epithelial cells in
vitro. Expression of interleukin-6 (IL-6), a cytokine involved in the inflammatory
response, and intercellular adhesion molecule-1 (ICAM-1), a cell surface molecule
involved in leukocyte extravasation, was measured following exposure to CNT and CLP
at concentrations of 1 µg/cm-2 and 10 µg/cm2 [29-31]. The fold difference in expression
of IL-6 between CNT and CLP when normalized to the 1 µg/cm2 CNT group is
illustrated in Figure 2.3E. At 10 µg/cm2 the expression of IL-6 for CNT was nearly three
fold higher than for CLP. Moreover, ICAM-1 expression following CNT exposure at 10
µg/cm2 was approximately 50% higher than the CLP (Figure 2.3F), indicating that
coating CNT with PLA-PEG significantly decreased both toxicity and inflammatory
response compared to non-coated CNTs.
nGr was also coated with PLA and PEG. Dose-dependent toxicity studies of nGr
and nGrLP with U-138 glioblastoma showed that PLA-PEG coating decreased the
toxicity associated with nGr. Figure 2.4 shows Live/Dead staining of U-138 cells after
24 hr exposure to uncoated nGr, and nGrLP. Cells treated with nGr showed dose
dependent toxicity compared to the live cell control. With increasing concentrations of
nGr there appeared to be not only more dead cells (red), but also a decreased cell
population. Cells treated with nGrLP did not appear to have significantly more dead cells
compared to the live cell control, and also did not display a decrease in cell population.
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Figure 2.3 In vitro studies illustrate the uptake, toxicity, and inflammatory response of
CNT-PLA-PEG (CLP). (A,B) Confocal microscope images show the uptake of
fluorescently loaded CLP particles (red) in HUVEC and U-87 cells stained for actin
filaments (green) and cell nuclei (blue). Scale bars represent 50 µm. (C,D) Toxicity
studies of CNT and CLP in HUVEC and U-87 cells showed that polymer coating
decreased NP toxicity. *indicates significant difference between each sample and the 0
µg/ml concentration, determined by Tukey’s HSD test. (E,F) Polymer coating on CNTs
also decreased expression of inflammatory cytokines IL-6 and ICAM-1.
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Figure 1.4 Live/Dead assay showed live U-138 cells (green), and dead cells (red). nGr
showed dose-dependent toxicity both by increased presence of dead cells, and lower cell
population density. nGrLP seemd to be relatively unaffected even at doses up to 25
µg/ml. Scale bars represent 500 µm.
In a controlled release study performed to quantify the amount of PTX released
from CLP (Figure 2.5A), we determined that CNT-PLA-PEG could load 1.65 wt.% PTX
and release the drug in a controlled manner for at least one week. To carry out in vitro
efficacy experiments, U-87 cells were incubated for 6 hours and at 24 hours with drug
loaded CLP to allow for nanotube uptake and intracellular release. Three different
amounts of NP were tested containing the equivalent concentrations of 70, 140, and 280
nM of PTX (Figure 2.5B) compared to free drug. At the end of the time point, cells were
washed with sterile PBS and allowed to grow for a total of 72 hours following initial
exposure to the nanoparticles. This data emphasizes the importance of rapid nanoparticle
uptake and controlled release due to short circulation time of free drugs.
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Figure 2.5 (A) Release of paclitaxel (PTX) from CNT-PLA-PEG (CLP) was monitored
by high performance liquid chromatography with the release sustained over a 1-week
period. (B) PTX toxicity with free drug compared to drug loaded CLP shows that NP are
more effective with shorter incubation time, apparently due to NP uptake and controlled
intracellular release. *indicates significant difference between each sample and the 0 nM
concentration, determined by Tukey’s HSD test.
Thus, this figure illustrates that the nanotubes are uptaken into the cells in as little as 6
hours and can mediate drug release over an extended period of time. Free paclitaxel
efficacy is significantly reduced when the cells are exposed to drug for a short period of
time (i.e. 6 hours). Free PTX at 140 nM incubated for 6 hours was only able to kill 12%
of cells, compared to the 50% viability after 24 hours of exposure to free drug. However
with the 6 hour incubation, CLP at a concentration equivalent to 70 nM of PTX was as
effective as free PTX at twice the concentration (140 nM). This demonstrates that, with a
shorter incubation time, CLP loaded with PTX was twice as effective as free PTX. A
Tukey’s HSD test showed that at 6 hr incubation with free drug or drug-loaded CLP, only
CLP loaded with the equivalent of 140 nM and 280 nM were significantly different than
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the 0 nM control (cell blank). CLP loaded with an equivalent of 280 nM, however was as
efficient after 6 hours of incubation as it was at 24 hours, perhaps due to the rapid uptake
of the drug delivery vehicle saturation and the intracellular controlled release of PTX. To
achieve a PTX concentration of 280 nM, a concentration of only 10 µg/cm2 CLP was
required. Therefore, only 3 µg of CLP loaded with PTX was able to eliminate 50% of U87 cells in a 96-well plate. These results illustrate the potential of CLP as a safe, potent
mediator of drug delivery and cancer therapy using low doses of CNTs.

2.2.3. In Vivo Biodistribution in Mice
Biodistribution studies in Balb/c mice showed clearance of fluorescently loaded
CLP through the kidneys and bladder, as well as through the reticuloendothelial system,
i.e. the liver and spleen (Figure 2.6). NPs loaded with a fluorescent dye Alexa Fluor 647
were administered via tail vein injection at a dose of 10 mg/kg to enable live animal
imaging with an IVIS Lumina XR small animal imaging system. Animals were imaged at
5 minutes, 30 minutes, and 24 hours post injection (Figure 2.6A), and fluorescent images
show fluorescent signal from CLP in the bladder. Kostarelos et al. [11, 32-35] determined
that dispersed single-walled CNTs are cleared through the kidneys due to the alignment
of thin diameter tubes with the pores of the glomerulus, approximately 5-20 nm in
diameter. Our results suggest that some of the CLP nanotubes may be cleared via this
mechanism while the majority of tubes are cleared via the liver and spleen similar to
other nanomaterial drug delivery systems. Mice were euthanized and organs were
explanted for fluorescent imaging after 24 hours. Figure 2.6B shows representative
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images of the fluorescent signal in the spleen (iii) and liver (iv) from three repetitions. In
addition to fluorescent biodistribution studies, mice were injected with saline, pristine
CNT, CL, and CLP to analyze tissues using histology after 24 hours. Figure 2.7 shows
the representative haematoxylin and eosin (H&E) staining of the liver, spleen, lung, and
brain. Bright field microscope images show the accumulation of CNT aggregates in the
lungs, liver, and spleen, with CL aggregates also in the liver, lung, and brain. In contrast,
though CLP particles were found in the lungs and brain, the images suggest no CLP
aggregation.

Figure 2.6 (A) Representative images of live Balb/c mice injected intravenously with
saline, fluorescently loaded CNT-PLA (CL), or fluorescently loaded CNT-PLA-PEG
(CLP) showed clearance through the bladder. (B) Fluorescent imaging of explanted
organs after 24 hr shows accumulation of fluorescent signal in the spleen, liver, and
brain. Organs shown are (i) muscle, (ii) fat, (iii) spleen, (iv) liver, (v) kidneys, (vi) heart,
(vii) lung, and (viii) brain.
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Figure 2.7 Hematoxylin and eosin (H&E) staining of mouse organs following
intravenous administration of saline, CNT, CNT-PLA, and CNT-PLA-PEG showed some
deposits of NP in tissue. NPs are indicated with black arrows and white scale bars
indicate 50 µm.
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Biodistribution studies of CLP and nGrLP mice showed the passive accumulation
of NP within intracranial U-138 tumor xenografts in nude Balb/c mice. Tumors were
implanted within mice brains, and fluorescently tagged CLP or nGrLP were administered
intravenously. Time-course studies with fluorescent imaging showed that both CLP and
nGrLP accumulated within brains within 1 hr after injection (Figure 2.8A). There also
appears to be strong fluorescent signal for nGrLP localized in the mouse spleen.
Fluorescent imaging of explanted organs showed most nanoparticle accumulation in the
liver, and spleen (Figure 2.8B). There was strong signal from the brain for both CLP and
nGrLP, indicating passive accumulation of NP within tumors. There was also some
accumulation of nGrLP in lungs. Thus, it appears that difference between fibrillar NP
(CLP) and plate-shaped NP (nGrLP) leads to differences in NP biodistribution and
accumulation in tissues.

2.2.4. In Vivo Inflammatory Response and Toxicity
Inflammatory response in C57BL/6 mice was monitored following the pulmonary
instillation of both CNT and CLP. Lung tissue was collected 30 days after pulmonary
instillation and stained with Masson’s trichrome (Figure 2.9A-C). Figure 2.9B shows
that mice instilled with CNT clearly had aggregates throughout the lung tissue, with some
inflammation, slight granuloma formation around the CNT aggregates, and a small
amount of collagen deposition. No CNTs were visible with the CLP group when the
entire lung was analyzed with histology (Figure 2.9C). Thus, the CLP particles
effectively reduced the inflammation following instillation in the lungs.
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Figure 2.8 In vivo biodistribution of fluorescently tagged CLP and nGrLP showed
accumulation in intracranial tumors. (A) Time-course study of intravenously
administered CLP and nGrLP showed accumulation in tumors and in organs such as the
spleen, kidney, and liver. (B) Explanted tissues showed accumulation in the liver,
kidneys, some lung, and brain (tumor). (i) fat, (ii) spleen, (iii) liver, (iv) kidneys, (v)
heart, (vi) lungs, (vii) brain.
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The inflammatory response was further investigated following pulmonary
instillation in mice via bronchoalveolar lavage (BAL). Though macrophages collected
from BAL were shown to uptake pristine CNT (Figure 2.9E), none containing CLP were
found following pulmonary instillation. Figure 2.9G shows the percent of alveolar
macrophages containing CNTs, comparing pristine CNT to PLA-PEG coated CNT. The
results demonstrate that coating CNT in PLA-PEG can mitigate the inflammatory
response associated with CNTs, possibly due to decreased NP aggregation and by
imparting a hydrophilic superficial coating.
The polymer coating also increased the CNTs maximum tolerated dose. In a dose
escalation study, Balb/c mice were injected intravenously via the tail vein with increasing
amounts of either pristine CNT or CLP. Five mice were injected at each concentration. At
25 mg/kg; 85% of mice injected with pristine CNT expired in less than two minutes.
However, all CLP mice injected at 25 mg/kg (not shown) and 40 mg/kg survived.
Importantly, 60% of mice injected with CLP at 50 mg/kg survived. Figure 6h shows a
Kaplan-Meier survival curve of mice injected with pristine CNT or CLP. Coating CNT
with PLA-PEG reduces acute toxicity associated with intravenous administration of
CNTs, possibly due to decreasing particle aggregation and thus decreasing capillary
blockage and NP accumulation in the lungs as shown with histology analysis [36-38].
Moreover the maximum tolerated dose of coated CNT was twice greater compared to the
pristine CNT.
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Figure 2.9 C57BL/6 mice underwent pulmonary aspiration of either saline or 2 mg/kg of
CNT or CNT-PLA-PEG (A-G). Masson’s trichrome staining of lung tissue of (A) saline,
(B) CNT, and (C) CLP showed that CNT caused mild inflammation. Alveolar
macrophages were collected via bronchoalveolar lavage following pulmonary instillation
of NP (D-G). Arrows in (E) indicate macrophages containing CNT. No CLP particles
were detectable in macrophages (F, G). Kaplan-Meier survival curves for Balb/c mice
receiving intravenous tail vein injections of CNT or CLP (H) show that the polymer
coating increases the maximum tolerated dose of CNT.
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2.3. Conclusions
In this work we showed that an amphiphilic polymer coating on the surface of
CNTs could reduce toxicity and increase therapeutic efficacy via the controlled delivery
of the anticancer drug PTX. Here, the PLA layer serves to encapsulate and mediate the
controlled release of hydrophobic drugs, while the PEG layer serves to improve aqueous
solubility and improve pharmacokinetic properties. This CLP drug delivery system was
significantly less toxic in both in vitro and in vivo when compared to pristine CNTs with
a maximum tolerated dose of approximately 50 mg/kg and 25 mg/kg, respectively.
Moreover, PTX-loaded CLP at equivalent concentrations of 70 nM Ptx was as effective
as free PTX incubated for 6 hr at 140 nM. This approach for functionalizing inorganic
nanoparticles (e.g. CNTs) illustrates how multifunctional polymer coatings can enable a
previously unsuitable nanomaterial for biomedical applications.
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CHAPTER THREE
MULTILAYERED POLYMER COATINGS TO CONTROL DRUG DELIVERY
Nanoparticles (NP) have been the subject of significant research as a
methodology for controlled drug delivery. However, monolayered nanoparticles
generally exhibit an initial non-ideal “burst” release, which limits the delivery of drug for
prolonged periods [1, 2]. Utilizing multilayered particles may improve drug delivery
capabilities. Here we report a one-pot room temperature ring-opening polymerization
approach to functionalize carbon nanotubes (CNT) with multiple polymer layers
composed of poly(glycolide) (PGA), poly(lactide) (PLA), poly(lactide-co-glycolide)
(PLGA) and poly(ethylene glycol) (PEG) to tailor drug delivery and improve therapeutic
efficacy compared to single layer coated CNTs.

3.1. Principles of Controlled Drug Release
Multilayered particles offer a solution to impart better control over drug release
characteristics when compared to single layer particles. Loo, Lee, and Widjaja [3-7]
reported multilayered microparticles composed of PGA, PLA, PLGA, poly(caprolactone)
(PCL), poly(styrene) (PS), and poly(ethylene-co-vinyl acetate) (EVA) that controlled the
release of the model drugs ibuprofen, metoclopramide HCl, and lidocaine [3].
Multilayered particles were fabricated via an emulsion solvent evaporation method
resulting in an EVA core, with PS, PLA, and PLGA shells. These particles not only
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altered the release kinetics, but the polymers exhibited spatial separation of drug loading
within distinct layers [3, 4]. While single layered microparticles generally exhibited an
initial burst release, closer to zero-order release kinetics were achieved with the use of
multilayered particles. Multilayered microparticles have been previously fabricated using
one-step solvent evaporation [3], biomimetic solution polymerization [8], spray draying
[9], layer-by-layer assembly [10], and liquid jets with acoustic disruption [11, 12]. With
CNTs as a nanoparticle template, we created a controlled drug delivery system for the
anticancer drug dasatinib (DAS) by polymerizing multiple polymer layers directly onto
CNTs.

3.2. Methods for Multilayered Coatings to Control Drug Release
A variety of methods have been developed to functionalize CNTs as mechanisms
for delivering drugs [13-19]. Liu et al. [16, 17, 20, 21] functionalized CNT surfaces using
a phospholipid-PEG molecule, whereby the phospholipid strongly adsorbs to the CNT
surface and the PEG improves aqueous dispersion. Drug molecules could be further
adsorbed to the CNT surface [17] or PEG could be modified to attach drugs [16]. Another
approach involves the direct conjugation of drug to the CNT surface. Dhar et al. [22]
conjugated a prodrug that is reduced intracellularly to release cisplatin. Previously, we
have demonstrated that monolayer polymer coated CNTs can release paclitaxel for one
week, improve therapeutic efficacy against U-87 glioblastoma compared to free drug, and
reduced CNT-associated toxicity in vitro and in vivo. Here, we report a one-pot “grafting
from” approach to sequentially add either block copolymers or random copolymers, i.e.
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PGA-PLA or PLGA, where the polymer coating thickness can also be controlled.
Capping the ring opening polymerization with PEG improved the aqueous stability of
these coated CNTs. The significance of this work is that (1) synthesis occurs via a onepot reaction at room temperature using organocatalysts; (2) CNTs are coated with
multiple layers to control drug release kinetics. Figure 3.1 illustrates the approach for
polymerizing multiple polymer layers onto carbon nanotubes at room temperatures in a
one-pot reaction.
CNT-OH

CNT-OH

P2-t-Bu
24hr

P2-t-Bu
24hr

CNT-PGA

CNT-PLA

P2-t-Bu
24hr

P2-t-Bu
24hr

CNT-PGA-PLA

CNT-PLA-PGA

6hr

6hr

CNT-PGA-PLA-PEG

CNT-PLA-PGA-PEG

Figure 3.1 Hydroxyl-functionalized carbon nanotubes (CNTs) were coated with multiple
layers of poly(glycolide) (green) or poly(lactide) (blue) via a one-pot synthesis approach.
Monomers were added sequentially into the reaction to yield distinct layers of polymer
coating on CNTs. Methoxy-poly(ethylene glycol)-isocyanate (red) was added to cap the
reaction and impart an amphiphilic coating able to sequester hydrophobic drugs and
disperse in aqueous solution.
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Table 3.1 Experimental plans for multilayered nanoparticles.

3.2.1. One-pot Room Temperature Ring-opening Polymerization
Hydroxyl-functionalized multi-walled carbon nanotubes (MWCNT-OH) were
purchased from Sun Innovations, Inc. (Fremont, CA). D,l lactide was purchased from
Purac Biomaterials (Lincolnshire, IL). Methoxy-poly(ethylene glycol)5k-isocyanate
(mPEG-isc) was purchased from Nanocs, Inc (New York, NY). Glycolide, εcaprolactone, phosphazene base 1-tert-butyl-2,2,4,4,4-pentakis(dimethylamino)-2Λ,54Λ5catenadi(phosphazene) (P2-t-Bu), and all solvents were purchased from Sigma-Aldrich.
All reagents were dried overnight under 28 in Hg. Next, both CNT and monomer were
dissolved in 4 mL of acetonitrile (ACN) by stirring for 30 min. Phosphazene base P2-t-Bu
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was added as a catalyst and the reaction was continued overnight. The next day an aliquot
of sample was removed, washed, and lyophilized for analysis. The second monomer was
then dissolved in 2 ml of ACN and added directly into the reaction vessel. More P2-t-Bu
was added, the reaction vessel, and the reaction was continued overnight. Next, mPEGisc was dissolved in 2 ml of ACN and added directly into the reaction vessel. The product
was lyophilized and stored at -20 °C under N2. TGA was performed on a TA Instruments
Hi-Res TGA 2950 thermogravimetric analyzer under nitrogen from 25 °C to 600 °C at 20
°C/min. Transmission electron microscopy was performed on a Hitachi H7600T at
115kV.

3.2.2. Dasatinib loading and release.
Dasatinib (DAS) was purchased from LC Laboratories (Woburn, MA). High
performance liquid chromatography (HPLC) was used to determine the release kinetics
of DAS from coated CNTs. DAS was encapsulated by dissolving coated CNTs at 5
mg/ml in a solution of DAS. This CNT/DAS solution was then dropped at a 1:2 ratio in
HyPure water and stirred for 2 hours, and DAS was encapsulated via solvent evaporation.
Samples were washed three times in HyPure water via centrifugation. DAS-loaded CNTs
were re-dispersed in HyPure water and added to the top of a 3.5 kD Slide-a-Lyzer MINI
dialysis unit. Each dialysis unit was placed in a 1.5 ml microcentrifuge tube containing
HyPure water. Five repeats per formulation were used and samples were stored at 37 °C.
At each time point dialysate was removed and frozen, and fresh HyPure water was
replaced. Lyophilized aliquots were analyzed via HPLC on a Waters 1525 Binary HPLC
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pump with a 2998 photodiode array detector. An Alltima C18 column (4.6 x 25 mm, 5
µm) was used with mobile phase of 50/50 solution of ACN and 0.4 v/v% triethylamine
(TEA) in water. The mobile phase flow rate was 0.8 ml/min and DAS was detected at a
wavelength of 280 nm with an average elution time of 7.5 minutes.

3.2.3. Cell Culture.
U-87 glioblastoma and Eagle’s minimum essential medium (EMEM) were
purchased from American Type Culture Collection (Manassas, VA). Fetal bovine serium
(FBS) was purchased from Atlanta Biologicals (Lawrenceville, GA). U-87 glioblastoma
cells were grown in EMEM supplemented with 10% FBS and 1% penicillinstreptomycin. Cells were subcultured at 35 °C and 5% CO2. To test DAS efficacy in
vitro, U-87 cells were seeded at 10,000 cells/well in a 96-well plate. DAS was loaded as
previously described and drug loaded CNTs were incubated with cells at 10 µg/ml. Free
DAS was prepared by first dissolving at 0.1 mg/ml in DMSO and diluting 1:1000 in
EMEM. Fresh media, free DAS, or DAS-loaded CNTs were added to cells and incubated
for 6hr or 24 hr. There were five repeats per formulation. After the initial time point,
media was removed and cells were washed gently with EMEM. Cells were incubated in
in fresh EMEM and incubated for a total of 72 hr after initial exposure to free drug or
CNTs. Cell viability was measured with a Presto Blue assay by comparing fluorescent
intensity of each formulation to the average fluorescent intensity of cells grown in only
media.

87

3.3. Results and Discussion
3.3.1. Preparation and Characterization of Mutilayered Carbon Nanotubes
Commercially available CNTs functionalized with surface hydroxyl groups were
coated by initiating the ring-opening polymerization of glycolide directly on the CNT
surface using phosphazene base P2-t-Bu in anhydrous acetonitrile [23-25]. A CNT coated
with a layer of PGA (CNT-PGA-OH) was the result. As PGA has a terminal hydroxyl
group, PLA was directly polymerized from CNT-PGA-OH as a second layer by
introducing d,l lactide into the reaction vessel. A multilayered coating of PGA-PLA on
the CNT surface (CNT-PGA-PLA-OH) was the result. Finally, the polymer chain ends
were capped by introducing methoxy-poly(ethylene glycol)-isocyanate (mPEG-isc) into
the reaction vessel. Here the reactive isocyanate groups form a urethane linkage with
terminal hydroxyl groups on the polymer chain ends, thereby coating CNTs with an
external PEG layer (CNT-PGA-PLA-PEG) [26]. This capping step effectively terminated
the polymerization. Multilayer polymer coating was confirmed via thermogravimetric
analysis (TGA). Single layer CNTs was synthesized by simply introducing mPEG-isc
directly into the reaction after the first polymerization step (Figure 3.2). Single layer
CNTs

comprised

of

PLA-PEG,

PGA-PEG,

copolymer

PLGA-PEG,

and

poly(caprolactone)-poly(ethylene glycol) (PCL-PEG) were synthesized in this manner.
However, the synthesis of PCL-PEG encountered issues with repeatability, possibly due
to the liquid nature of the ε-caprolactone monomer. Therefore this formulation was not
pursued further.
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Figure 3.2 Thermogravimetric analysis of (A) CNT-PLA-PEG, (B) CNT-PGA-PEG, (C)
CNT-PLGA-PEG, and (D) CNT-PCL-PEG shows the successful synthesis of single
layered CNTs.
Polymer coating thickness can be controlled by varying the ratio of monomer (i.e.
glycolide or d,l lactide) to initiator (i.e. hydroxyl-functionalized CNT), and tunable levels
of PLA and PGA were polymerized onto CNTs. Moreover, the relative amounts of
polymer in the multilayered CNT were controlled in the same manner. Figure 3.3A
shows multilayered CNTs coated with a thin base layer of PGA (12 wt%) and a thick
outer layer of PLA (42 wt%). By changing the reaction conditions, however, a thick base
layer of PGA (48 wt%) and a thin outer layer of PLA (12 wt%) can be polymerized on
CNT surfaces (Figure 3.3B). The isocyanate capping was also validated via TGA;
Figure 3.3C shows TGA data for a multilayered CNT composed of all three polymer
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layers: 25 wt% PGA, 25 wt% PLA, and 6 wt% PEG. The order of the monomer
polymerization can also be changed. Figure 3.3D shows a multilayered CNT with 58
wt% PLA, 20 wt% PGA, and 10 wt% PEG. Single layer and multilayer coated CNTs
were further characterized via transmission electron microscopy (Figure 3.4). While the
thin single layer coating is difficult to discern, the multilayer coating clearly shows
aggregated CNT with polymer coating. This data further confirms the presence of a
polymeric coating on the carbon nanotubes.

Figure 3.3 Thermogravimetric analysis shows successful control of multilayered coatings
on CNTs. (A) By decreasing the initial monomer to initiator ratio it is possible to coat a
thin layer of PGA on CNTs, followed by a thick layer of PLA. (B) Conversely it is
possible to coat a thick layer of PGA and then have a relatively thin layer of PLA. (C)
PEG capping imparts a fully functional multilayered CNT with a PGA, PLA, and PEG
coating. (D) By altering the order of monomers added into the reaction it is possible to
get a CNT coated with PLA, then PGA, and finally PEG.
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By holding the mass of CNT constant and varying molar ratio of glycolide or d,l
lactide, the weight percent of polymer coating could be controlled (Figure 3.5). Thus,
this synthesis approach enables control over not only the thickness of the multiple layers,
but also the spatial organization of these layers.

Figure 3.4 Transmission electron microscope images at 100k magnification of CNT,
CNT-PGA, and CNT-PGA-PLA coated carbon nanotubes. The polymer coating can
clearly be seen with the multilayered coating. Scale bars represent 100 nm
3.3.2. Multilayered Nanoparticle Release Kinetics
Drug release kinetics of dasatinib (DAS), an Src/Abl kinase inhibitor [27, 28],
were measured with high performance liquid chromatography (HPLC), and single
layered CNTs were compared to multilayered formulations. Drug loading efficiency for
CNT-PLA, CNT-PGA, CNT-PLGA, and CNT-PGA-PLA was 0.4, 4.4, 1.7, and 3.5 wt%,
respectively. Thus, drug-loading efficiency of DAS is influenced by polymer composition
of the coating. Each formulation also showed different release kinetics (Figure 3.6).
Though DAS released immediately from PGA (instant), there was a lag time (delayed) in
the release of DAS from PLA coatings. This variation in DAS release kinetics is possible
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attributable to interactions between either the drug and the polymer matrix, or the
polymer degradation kinetics [29-33].

Figure 3.5 The thickness of polymer coated onto CNT surface can be controlled by
varying the ratio of monomer (i.e. glycolide or lactide) to CNT. (A) Poly(glycolide)
(PGA) coating thickness on CNT was shown to increase by increasing the molar amount
of glycolide in the reaction. (B) Poly(lactide) (PLA) exhibited a similar control over the
PLA thickness by varying the molar amount of d,l lactide in the reaction.
Random copolymer PLGA showed a steady release profile similar to PGA (instant). The
multilayered CNT-PGA-PLA released drugs in a near linear manner, however,
suggesting that multilayered coatings offer a means of controlling both the loading and
release profile.

3.3.3. In Vitro Efficacy of Drug-loaded Multilayered Particles
Controlling the release kinetics of DAS is expected to alter the therapeutic efficacy of
these CNT drug delivery vehicles. Cell viability data using U-87 glioblastoma suggests
that controlling release kinetics is critical for improving therapeutic efficacy of DAS,
which is being investigated as a treatment against recurrent glioblastoma [27, 34].
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Figure 3.6 Dasatinib release from polymer coated CNTs shows that a difference in the
polymer coating exhibits control over the release kinetics. PGA coated CNTs show the
quickest release. CNT-PLA had an initial lag period before release, and CNT-PLGA
showed release similar to that of CNT-PGA. Multilayered CNT-PGA-PLA showed
mostly linear release.
In Figure 3.7A, we show the efficacy of different DAS-loaded polymer coated CNTs
compared to free DAS.Cells were exposed to different formulations at 10 µg/ml for either
6hr or 24hr. The different incubation times ensures CNT uptake into cells. Cells were
washed after each time point and cell viability was determined at 72hr. The therapeutic
efficacy was measured by normalizing all formulations to cells treated with cell culture
media only. Multilayered CNTs showed significant improvement (40% viability) over
DAS loaded CNT-PLA-PEG (55% viability), and free DAS (75% viability). Results
showed that at both time points the PGA, PLGA, and multilayered formulations had
significantly higher cytotoxicity than the free DAS and PLA coated CNTs. This is
ostensibly due to the lag in release of DAS from PLA, and the low therapeutic loading in
the PLA-coated CNTs. Thus it is apparent that altering the release kinetics by controlling
the multilayered coatings on CNTs is critical to improving therapeutic efficacy.
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Figure 3.7 Cell viability assays using U-87 glioblastoma indicated that polymer coating
and dasatinib release kinetics result in different therapeutic efficacy. Cells were incubated
with different formulations at 10 µg/ml for 6hr or 24hr and viability was tested at 72hr
after initial exposure to drug loaded CNT formulations. (A) Multilayered CNT-PGAPLA-PEG drug loaded formulations had significantly higher cytotoxicity to U-87
compared to monolayer formulations at 24hr exposure. (B) Multilayered CNT
formulations also improved efficacy compared to spherical PLA-PEG nanoparticles.
After 24hr incubation, the DAS-loaded multilayered CNT-PGA-PLA-PEG formulation
had lower cell viability viability than the monolayer formulations. The in vitro efficacy of
polymer coated CNTs was compared to spherical polymeric PLA-PEG nanoparticles
(Figure 3.7B). This data suggests that multilayered CNTs are also more effective than
polymeric PLA-PEG nanoparticles to kill U-87 cells with DAS.

3.4. Conclusions
In conclusion we have reported a one-pot, room temperature synthesis to coat
multiple polymer layers on CNTs for drug delivery applications. These multilayered
coatings on the surface of CNTs are able to sequester hydrophobic drug, tailor drug
release kinetics of DAS, and improve therapeutic efficacy against U-87 glioblastoma in
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vitro. The synthesis occurs through a surface initiated ring opening polymerization using
phosphazene base catalysts. Step-wise addition of different monomers allows for multiple
polymer layers on the CNT surface. Multilayered coatings adopted release characteristics
of both homopolymers PGA and PLA. Moreover, multilayered coating of PLA-PGAPEG significantly improved therapeutic efficacy in vitro against U-87 compared to
monolayered coatings. Coating nanomaterials with multiple layers of polymers has broad
impact for drug delivery applications.
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CHAPTER FOUR
RADIOLUMINESCENT NANOPARTICLES FOR IMAGING DRUG DELIVERY
Theranostic nanomedicines are expected to improve cancer therapy by monitoring
drug delivery, drug release, and drug efficacy. Continuous monitoring of drug
biodistribution and intratumoral concentration would provide critical real-time feedback,
and allow clinician’s to adjust treatment regimens in a personalized manner [1, 2].
Moreover, nanoparticle drug delivery systems (NPDDS) have been shown to increase
localization of drug to tumor sites passively through the enhanced permeability and
retention effect [3, 4], or through active targeting [5-7]. NPDDS are subsequently able to
subvert some of the more limiting side effects of chemotherapy by decreasing systemic
toxicity, increasing intratumoral concentration of drug, and improving therapeutic
efficacy due to nanoparticle (NP) uptake into cells. Early theranostic nanoparticle
systems were able to combine drug delivery with nanoparticle imaging [8-10]. However
current technologies are aiming to develop theranostic nanomedicines able to
quantitatively report in situ drug doses [5, 11-14].

4.1. Quantitative Approaches to Measure Drug Release
Recently, luminescent nanoparticles have been investigated as a means for
measuring drug release kinetics in situ. Radioluminescence is a phenomenon whereby
radiation energy (e.g. X-ray) is converted into visible light. As X-rays possess excellent
soft tissue penetration, radioluminescence offers an appealing approach for measuring
drug release. Radioluminescent nanoparticles have been previously investigated for drug

100

delivery and biomedical imaging applications [14-17]. This approach provides deep
tissue penetration, and avoids complications from tissue autofluorescence. Previously,
porous nanocapsules of gadolinium sulfoxide (Gd2O2S) doped with terbium (Gd2O2S:Tb)
or europium (Gd2O2S:Eu) were shown to exhibit radioluminescence at excitation
wavelengths of 544 nm or 621 nm, respectively [14]. Moreover by choosing optically
absorbent drugs (e.g. doxorubicin), it was possible to measure the release of drug from
radioluminescent nanocapsules due to the return of luminescent intensity as the drug is
released. Radioluminescence of drug-loaded nanocapsules is quenched because there is
overlap in the x-ray luminescent spectrum of the nancapsules and the drug absorption
spectrum. Thus, as drug is released, radioluminescent intensity of the particle returns.
With optically absorbent drugs it is therefore possible to develop a theranostic
nanoparticle system capable of delivering drug and quantitatively measuring drug
loading.
Protoporphyrin IX (PpIX) is a photosensitizer (PS) used clinically in
photodynamic therapy (PDT) [18, 19]. Clinically, PpIX is traditionally administered as its
prodrug 5-aminolevulinic acid, which is biosynthetically converted into PpIX in vivo.
NPDDS have been used to both deliver photosensitive drugs, and act as the stimulus for
drug activation [13, 20-23]. Cui et al.[22] reported upconversion nanoparticles (UCNP),
NP able to convert near infrared (NIR) light into visible light, to deliver zinc(II)
phthalocyanine (ZnPc). Deep-tissue activation of ZnPc, a photosensitive drug, was
possible because of the improved penetration of NIR light through tissue to activate the
UCNP, which in turn activated ZnPc.
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To develop theranostic nanoparticles, spherical Gd2O2S:Eu nanoparticles were
coated with poly(glycolide)-poly(ethylene glycol) (PGA-PEG) for the controlled delivery
of PpIX. Quenching of Gd2O2S:Eu-PGA-PEG (XGP) radioluminescence by PpIX was
dose dependent, and NP could be used to measure drug loading concentration. XGP
maintained radioluminescence after polymer coating and could be used for imaging in
tissue ex vivo. Intracranial U-138 glioblastoma xenografts in nude mice showed that
systemically administered NP accumulated in brain tumors and could be imaged noninvasively using radioluminescence. Finally, coated and uncoated NP were shown to be
relatively non-toxic at a dose up to 25 µg/ml in U-138 glioblastoma in vitro, and in
Balb/c mice after injections up to 100 mg/kg.

4.2. Methods for Theranostic Radioluminescent Nanoparticles
4.2.1. Gd2O2S:Eu Nanoparticle Synthesis
Gadolinium(III) nitrate, europium(III) nitrate, urea, glycerol, sodium fluoride,
sulfur powder, ammonium hydroxyide, glycolide, tetraethyl orthosilicate, and all solvents
were purchased from Sigma-Aldrich. Gadolinium(III) nitrate (Gd(NO3)3) was dissolved
in 2L distilled water (diH2O). Europium(III) nitrate (Eu(NO3)3) was added at a
concentration of 200 mM. Nanoparticles were collected via centrifugation and washed
with diH2O. Nanoparticles were re-dispersed in 20 ml diH2O. Sodium fluoride (NaF) at
was dissolved in diH2O and 4 ml of NaF solution were added to the nanoparticle solution.
After stirring for 1hr, solution was cooled to room temperature and washed with diH2O.
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Table 4.1 Experimental plans for radioluminescent theranostic nanoparticles
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Nanoparticles were re-dispersed in 200 ml diH2O and sonicated. Nanoparticles were
heated to 80 °C to dry. Nanoparticles were heated at 600 °C for 2 hours to remove
impurities. Nanoparticles were collected and cooled to room temperature.

4.2.2. Amine-functionalization of Gd2O2S:Eu Nanoparticle Functionalization
20 ul TEOS was added to the solution after the solution was stirred for 10 min.
The particles were stirred and aged at room temperature for two hours. After that, 20 ul
(3-aminopropyl) triethoxysilane (APTES) was added to the suspension and the reaction
continued stiring for one more hour. The resulting particles were separated by
centrifugation and washed three times with ethanol.

4.2.3. Poly(glycolide)-poly(ethylene glycol) coating of Gd2O2S:Eu(NH2)
Nanoparticles were covalently coated with poly(glycolide) (PGA) using a room
temperature, ring-opening polymerization. In a typical reaction, 40 mg of
Gd2O2S:Eu(NH2) and varying amounts of glycolide were dissolved in 4 ml of acetonitrile
(ACN). 2M phosphazene base P2-t-Bu in tetrahydrofuran was added as a catalyst.
Methoxy-PEG-isocyanate (mPEG-isc), MW=5,000 Da, was purchased from Nanocs, Inc.
(New York, NY). Next, mPEG-isc was dissolved in 2 ml of ACN and added directly to
the reaction mixture. The product was lyophilized and stored at -20 °C under nitrogen.
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4.2.4. Nanoparticle characterization
Chemical composition was analyzed FT-IR was performed with a ThermoNicolet Magna 550 equipped with a Thermo-SpectraTech Foundation series Endurance
Diamond ATR. Thermogravimetric analysis was performed on a Hi-Res TGA 2950
thermogravimetric analyzer (TA Instruments, New Castle, DE) under nitrogen from 25
°C to 600 °C at 20 °C/min. Transmission electron microscopy was performed on a
Hitachi H7600T transmission electron microscope at 115 kV. For radioluminescence
experiments, X-ray was generated by a mini X-ray tube (Amptek Inc, Bedford, MA,
USA) operated at a tube voltage of 40 kV and a tube current of 99 µA.
Radioluminescence measurements were taken by a DMI 5000M microscope (Leica,
Wetzlar, Germany) equipped with a DNS 300 Spectrometer (Intevac-DeltaNu, Laramie,
WY, USA) with a 150 lines/mm grating blazed at 500 nm and with a cooled iDUS420BV CCD camera (Andor, South Windsor, CT, USA). Ex vivo and in vivo
radioluminescence images were captured with an IVIS Lumina-XR imaging system
(Caliper Life Sciences, Hopkinton, MA, USA).

4.2.5. Radioluminescent Drug Quenching and Release Measurements
Radioluminescence measurements were taken to compare empty NP and PpIXloaded NP. Briefly, NPs were loaded with PpIX via solvent evaporation. PpIX was
dissolved at varying concentrations in an 80/20 solution of acetonitrile/dimethyl
sulfoxide. NP were then dissolved in this PpIX solution at 5 mg/ml. NP were dropped at
1:2 ratio of PpIX/NP solution in HyPure H2O. Mixture was stirred for 2 hours to

105

evaporate solvent. NP were washed 5x in HyPure H2O to remove excess drug. Drug
loaded NP were re-dispersed at 25 mg/ml in HyPure water and added to a chambered
slide. Radioluminescent signal was measured with the spectrometer. Signal was analyzed
by comparing the average intensity across the 630 nm peak to the average intensity across
the 700 nm peak. PpIX is attenuates luminescence at 630, however has little absorbance
at 700 nm. Therefore, comparing the 630 nm intensity to the 700 nm intensity provides a
normalize measurement of signal attenuation.
Radioluminescence measurements were achieved similarly in pork tissue. Pork
tissue was diced into cubes and placed into an 8-chambered glass slide. PpIX was loaded
as previously described and NP were injected at 20 mg/ml into pork tissue.
Radioluminescent intensity was measured with the spectrometer and signal ratios were
calculated as previously described.
To measure drug release kinetics, coated NP were loaded with PpIX as previously
described at a PpIX concentration of 1 mg/ml. After washing via centrifugation, NP were
re-suspended at 10 mg/ml in HyPure water and placed into the top of 3.5kD Slide-ALyzer MINI dialysis unit. These were placed in 2 ml microcentrifuge tubes with HyPure
water and stored at 37 °C protected from light. At each time point, microcentrifuge tubes
were exchanged with fresh water and dialysate was lyophilized for future analysis. 50 µl
of the top NP solution was removed and placed in a chambered slide for X-ray
spectrometer measurements. X-ray spectrometer measurements were taken with 15
second exposure, and radioluminescent intensity for PpIX-loaded NP was compared to a
blank control (unloaded NP).
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4.2.6. In Vitro Cellular Uptake in U-138 Glioblastoma
Uptake of coated NP in U-138 glioblastoma was measured via radioluminescent
intensity. Cells were seeded at 1,000,000 cells per T-25 flask. After allowing cells to
attach overnight, coated NP were added to cells at 25 µg/ml and incubated for varying
time points. At each time point cells were washed 2x with sterile PBS. Cells were then
treated with 1 ml of trypsin and then centrifuged at 1,000 rpm for 5 minute. Trypsin
supernatant was removed, being careful not to disturb the cell pellet. Samples were stored
at 4 °C protected from light until all time points were completed. NP uptake was
measured by taking radioluminescent images in the IVIS Lumina XR with the mini X-ray
tube operated at a tube voltage of 40 kV and a tube current of 99 µA as the excitation
wavelength and a DsRed emission filter. Uptake was quantified by taking region of
interest measurements compared to a cell blank (i.e. no NP).

4.2.7. Ex Vivo and In Vivo Radioluminescence Imaging
Radioluminescent imaging in deep tissue was accomplished using the IVIS
Lumina XR live animal imaging system. Porcine liver was a gift from Snow Creek Meat
Processing (Seneca, SC). Nanoparticles were injected 1 cm deep into liver tissue and
imaged with the IVIS small animal imaging system. Fluorescent Trilite Red quantum
dots (Crystalplex, Fremont, CA) with an emission wavelength of 630 nm were injected as
a control. Fluorescence images were taken using the IVIS Lumina XR with excitation
wavelength of 430 nm and DS red filter. Radioluminescent images were taken using the
bioluminescence setting of the IVIS system with the filter set at DSRed. X-ray was
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generated using a mini X-ray tube operated at a tube voltage of 40 kV and a tube current
of 99 µA.
For in vivo biodistribution studies, nude Balb/c mice were implanted with
intracranial tumors of U-138 glioblastoma following the protocol of Ozawa et al [24].
Briefly, U-138 cells were washed with sterile phosphate buffered saline (PBS). Cells
were collected and concentrated in serum-free media at 40,000,000 cells/ml. 100 µl of
cell suspension was added to 100 µl of matrigel. Athymic nude Balb/c mice were
anesthetized with ketamine-xylazine. Skin was disinfected with chlorohexidine and eyes
were lubricated with eye ointment. A 1 cm sagittal incision was made across the top of
the skull. The skull was sterilized with hydrogen peroxide. A hole was made 2 mm
anterior and 1 mm lateral of the bregma using a 25-gauge needle. 3 µl of cell/matrigel
solution was injected ~3 mm deep into the brain over 1 min. The skull was closed using
dental cement and the incision site was stapled shut. Tumors were allowed to grow for 10
days. After 10 days, biodistribution studies were performed. Nanoparticles were prepared
via the solvent evaporation approach without drug as described previously. Samples were
washed in sterile HyPure H2O and re-dispersed in sterile PBS at 1 mg/ml. 200 µl of NP
was administered via a tail vein injection. Animals were euthanized at 24 hours and
radioluminescent images were taken with the IVIS.

4.2.8. In Vitro Toxicity
U-138 cells were seeded at 10,000 cells per well in a 96-well plate (Corning) with
five repeats per test concentration. Gd2O2S:Eu and Gd2O2S:Eu-PGA-PEG were prepared
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by solvent evaporation in HyPure water. Solutions were stirred for 2 hours, washed by
centrifugation. NP were then re-dispersed in media and added to cells at different
concentrations. Cells were incubated with the NP for 24 hours at 37°C and 5% CO2.
Next, NP media was removed and cells were gently washed twice with PBS. A Presto
Blue cell viability assay (Life Technologies) was performed by mixing Presto Blue
reagent at a 1:9 ratio with cell culture media. 100 µl of working solution was added to the
cells and incubated protected from light for 45 minutes at 37°C and 5% CO2. Fluorescent
intensity was measured with a BioTek Synergy 4 plate reader at an excitation wavelength
of 560 nm and emission wavelength of 590 nm. Cell viability was determined by
normalizing fluorescent intensity to the average intensity of five wells of cells only
treated with media.

4.2.9. In Vivo Maximum Tolerated Dose
Animals were housed at Clemson University’s Godley-Snell Research Center. All
studies were done in accordance with Clemson Institutional Animal Care and Use
Committee (IACUC) approved protocols. For the maximum tolerated dose studies,
Balb/c mice were injected with NP at varying concentrations relative to body mass. NPs
were prepared as previously described via solvent evaporation. After washing, NPs were
re-dispersed in sterile PBS at concentrations determined by mouse body mass. NP
solutions were sonicated just prior to injection. Following injection mice were monitored
for 6 hours for signs of distress or deteriorating conditions. Mouse body mass and food
consumption was monitored every day for one week following injection. Subjects whose
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body mass went below 20% of initial body mass or who were non-responsive were
euthanized immediately via CO2 asphyxiation, followed by cervical dislocation as a
secondary means for euthanasia. All subjects were euthanized at the final time point per
IACUC protocol requirements.

4.3. Results and Discussion
4.3.1. Preparation and Characterization of Polymer Coated Radioluminescent Particles
Radioluminescent nanoparticles were fabricated by doping the precursor
Gd2O(CO3)2 H2O with the rare earth ions via urea precipitation in aqueous solution.
Particle surfaces were then functionalized with amines via the adsorption of APTES.
Next, surface amine groups were used to initiate the ring opening polymerization of
glycolide, as previously described in Chapters 2 and 3. PEG capped the reaction resulting
in Gd2O2S:Eu particles coated with PGA-PEG. Figure 4.1 shows the characterization of
coated and uncoated particles. Thermogravimetric analysis (TGA) reveals a polymer
coating with approximately 20 wt% PGA and 10 wt% PEG. Fourier transform infrared
spectroscopy (FTIR) shows the presence of a polymer coating, with a carbonyl stretch
peak from PGA at 288 cm-1. Moreover, transmission electron microscopy images show
aggregates of uncoated nanoparticles, and PGA-PEG coated nanoparticles. Photographs
under white light, and under X-ray radiation showed that radioluminescence was
preserved even with polymer coating. Uncoated and coated samples were photographed
under visible light, and under X-ray excitation in the dark.
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Figure 4.1 Characterization of radioluminescent nanoparticles. (A) Thermogravimetric
analysis indicates multiple polymer coatings of ~20 wt% poly(glycolide) (PGA), and ~10
wt% poly(ethylene glycol) (PEG). (B) Fourier transform infrared spectroscopy (FTIR) of
uncoated and PGA-PEG coated particles confirms the presence of a polymeric coating.
(C) Transmission electron microscope images show aggregation of multiple uncoated
nanoparticles (left), and two aggregated nanoparticles coated with PGA-PEG (right).
Black scale bars represent 500 nm. (D) White light photograph (left) and X-ray
photoluminescent photograph (right) of coated and uncoated nanoparticles shows that
radioluminescence is maintained even after polymer coating.
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Thus, the synthesis of NP and subsequent coating via surface-initiated ring-opening
polymerization resulted in a system capable of imaging due to the inorganic Gd2O2S:Eu
core and drug delivery due to the PGA-PEG coating.

4.3.2. Quantifying Drug Loading in Coated Nanoparticles
Nanoparticles with spectral characteristics that overlap with those of drugs have
been previously used to measure drug release kinetics. Since drugs “quench” the
luminescent signal from the nanoparticles, drug release is directly related to the return, or
increase, in NP luminescence [13, 14]. Figure 4.2 illustrates the ability of the photoactive
drug

protoporphyrin

IX

(PpIX)

to

quench

Gd2O2S:Eu-PGA-PEG

(XGP)

radioluminescence. UV/Vis measurements of PpIX in dimethylsulfoxide (DMSO)
showed an overlap between PpIX absorbance at 630 nm and XGP radioluminescence at
627 nm. By increasing the concentration of PpIX loaded into the XGP particles,
radioluminescent signal at 627 nm could be quenched. Radioluminescence was quantified
by averaging the luminescent intensity across the full-width half-maximum (FWHM) of
the 627 nm and 700 nm peaks. The ratio of these two values for each formulation (loaded
with varying concentrations of drug) was normalized by the XGP with no PpIX loaded.
This value gave a “percentage of signal” quenched, and Figure 4.2C shows dose
dependent quenching of XGP with increasing PpIX loading. This data indicates that the
XGP can be utilized as a mechanism to measure the amount of drug loaded in XGP based
on the quenching of luminescence. This study was repeatable in pork tissue as shown in
Figure 4.2D.
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Figure 4.2 (A) UV/Vis spectrum of protoporphyrin IX (PpIX) in DMSO overlaid with
the radioluminescent spectrum of XGP. PpIX absorbance at 630 nm overlaps with the
luminescent peak of XGP at 627 nm. (B) XGP was loaded with PpIX using solvent
evaporation and varying the loading concentration of PpIX. Increased loading
concentration resulted in attenuation of the XGP radioluminescence due to PpIX
quenching of the 627 nm peak. XGP luminescent signal at 700 nm was not affected by
PpIX absorbance. (C) 627 nm peak signal was compared to the signal intensity of the 700
nm signal. The ratio of these signals was normalized by the radioluminescent signal of
XGP with no PpIX. Normalizing gives a percentage of XGP signal quenched, and
loading with a concentration of 5 mg/ml showed attenuation of approximately 50%
signal. (D) Radioluminescent quenching could be similarly measured in pork tissue.
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Pork tissue was diced and placed in an 8-chambered slide on the X-ray spectrometer.
Unloaded XGP, and XGP loaded at 2.5 and 5.0 mg/ml PpIX were injected approximately
1 cm deep into pork tissue. Radioluminescent measurements were made and
radioluminescent quenching in water and pork was compared as previously described.
These data suggest that the radioluminescent, polymer-coated NP maybe be used to
measure drug loading concentrations in XGP in deep tissue.

Figure 4.3 Release kinetics were measured via return of radioluminescent signal intensity
(red) or via PpIX content in release study dialysate (blue). Data shows that increase in
radioluminescent intensity can be correlated to the release of PpIX from XGP particles.

4.3.3. Kinetic PpIX Release Measurements
In a controlled release study performed to quantify the release of PpIX from XGP
(Figure 4.3), it was shown that PpIX release could be measured by the radioluminescent
signal of XGP. As PpIX was released from XGP over a 48 hr period, the luminescent
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intensity of XGP increased. This indicated that the radiolumescent peak ratio of XGP was
sensitive to the release of XGP. Figure 4.3A shows the radioluminescent intensity of
drug-loaded XGP over time compared to a blank, non-loaded sample. At 48 hr 100% of
blank luminescent intensity has returned. Measurement of PpIX content in dialysate from
the release study further confirmed the release of PpIX (Figure 4.3B). Thus, XGP may
have use as a sensor for not only measuring drug loading concentration, but also
measuring drug release kinetics due to radioluminescent properties.

Figure 4.4 Radioluminescent IVIS imaging of XGP uptake into U-138 cells. (A)
Luminescent images show increased uptake of XGP into cells over time. (B)
Quantification of luminescent intensity normalized by a cell blank show the fold increase
in luminescent intensity over time.
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4.3.4. Cellular Uptake of Coated NP
The kinetic uptake of XGP in U-138 glioblastoma was determined by measuring
radioluminescent intensity. T-25 cell culture flasks containing 1,000,000 cells were
incubated with XGP at 25 µg/ml for varying time points. At each time point, cells were
washed with PBS and collected by trypsinizing and centrifugation. Radioluminescent
images were taken on an IVIS Lumina XR live animal imaging system with X-ray
radiation used as the excitation wavelength and 1 second luminescent exposure through a
DsRed emission filter. Luminescent intensity was measured with the Lumina XR
software using the region-of-interest (ROI) tool. Luminescent intensity of cells incubated
with XGP was compared to a cell blank. Figure 4.4 shows the kinetic uptake of XGP at
3, 6, and 24 hr. Radioluminescent images show increasing signal strength of XGP in U138 (Figure 4.4A), and Figure 4.4B shows the fold increase in intensity over the cell
blank as measured by ROI intensity.

4.3.5. Ex Vivo Imaging in Porcine Liver and Biodistribution in a Xenograft Model
Radioluminescent

imaging

is

advantageous

for

imaging

due

to

no

autofluorescence, and deep penetration of X-ray due to minimal tissue scattering. It was
possible to image radioluminescent NP injected as 1 cm deep in tissue. Quantum dots,
fluorescent nanoparticles with narrow emission ranges that are excited by shorter
wavelength ultraviolet or visible light, are limited for in vivo imaging applications due to
tissue autofluorescence, and poor penetration of excitation wavelengths. Thus, by testing
the luminescent intensity of quantum dots (control) and radioluminescent nanoparticles
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injected deep into porcine liver tissue, it was possible to illustrate the advantages
radioluminescent NP. Fluorescent quantum dots (λex 430 nm, λem 630 nm) or
radioluminescent NP were injected into porcine liver tissue at 1 cm deep. As seen in
Figure 4.5, radioluminescent nanoparticles were clearly visible under X-ray excitation
through porcine tissue. However quantum dots, while vividly fluorescent under 430 nm
excitation (inset microcentrifuge photograph), were not visible through tissue. This is
possibly due to the attenuation of the 430 nm excitation wavelength in tissue.

Figure 4.5 IVIS luminescent images of saline, QD, and radioluminescent NP injections 1
cm deep in porcine liver tissue. Inset images of QD tubes show QD fluorescence under
430 nm excitation, but no luminescence after X-ray excitation. Radioluminescent inset
images show luminescence after X-ray excitation, and little fluorescent activity after
excitation at 430 nm. Luminescent images show that, while imaging QD in deep tissue is
not feasible, radioluminescent NP are visible.
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Figure 4.6 Biodistribution studies of athymic nude Balb/c mice with intracranial U-138
xenografts following intravenous tail vein injection of Gd2O2S:Eu-PGA-PEG NP showed
accumulation of nanoparticles in brain tissue. Dorsal and ventral images were taken with
the X-ray source beam focused superior and inferior to the transverse plain. Strong
luminescent signal was evident due to accumulation of NP in tumor xenografts by the
enhanced permeability and retention effect. X-ray source is evident on the right of each
photograph, and red circles emphasize the region excited by the X-ray beam.
Aside from imaging ex vivo, it was also possible to image accumulation of NP in
tumors in vivo (Figure 4.6). Athymic nude Balb/c mice were implanted with intracranial
U-138 glioblastoma xenografts, and mice were administered NP via tail vein injection.
Mice were euthanized 24 hr post-injection. Radioluminescent images were taken superior
and inferior of the transverse plain on the dorsal and ventral sides. Strong accumulation
of NP is shown in the U-138 glioblastoma xenografts. This is most likely due to the
accumulation of NP via the enhanced permeability and retention effect. Moreover, it was
possible to detect nanoparticles accumulating in the spleen and liver. Thus, nonspecific
mechanisms for tumor targeting (i.e. passive accumulation) are capable of accumulating
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NP in tumors, and a non-invasive radioluminescent method for imaging NP
biodistribution is possible.

4.3.6. In Vitro and In Vivo Toxicity
Toxicity in U-138 glioblastoma was determined in vitro. Cells were seeded in a
96-well plate and incubated with varying doses of Gd2O2S:Eu or polymer coated
Gd2O2S:Eu-PGA-PEG for 24 hours. Viability was determined using a Presto Blue cell
viability assay. Percent viability was measured by normalizing the fluorescent intensity of
cells treated with NP to the average fluorescent intensity of cells treated with only media.
Five repeats were used for each treatment group. As seen in Figure 4.7, both coated and
uncoated NP were relatively nontoxic at 25 µg/ml. At higher concentrations (100 to 250
µg/ml) both treatment groups were significantly more toxic than the media only control
(p-value < 0.05), and at 50 µg/ml the polymer coated NP was significantly more toxic
than the control. However, at all concentrations there were no significant differences
between the two formulations as determined by a Student’s t-test.
Maximum tolerated dose studies of Gd2O2S:Eu-PGA-PEG in Balb/c mice showed
no systemic toxicity in doses up to 75 mg/kg following intravenous tail vein injection. A
higher dose at 100 mg/kg lead to adverse side effects and the subject was euthanized at
72 hr (data not shown). NP toxicity is mediated by material, size, shape, surface
characteristics, and porosity. Previous maximum tolerated dose studies of inorganic
nanoparticles have shown dose-dependent toxicity ranging from 30-1000 mg/kg for silica
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NP [25, 26], or 25-50 mg/kg for carbon nanomaterials [27]. Thus, the toxicity of the
polymer coated Gd2O2S:Eu NP falls within ranges similar to other inorganic NP.

Figure 4.7 (A) In vitro toxicity of coated and uncoated NP in U-138 glioblastoma
showed no significant difference between the two formulations. (B) In vivo maximum
tolerated dose studies of Gd2O2S:Eu-PGA-PEG in Balb/c mice showed no systemic toxic
effects after intravenous administration after 1 week up to 75 mg/kg. Systemic toxicity
was determined by monitoring changes in percent body mass following injection. A drop
in <20% body mass was designated as toxic.
4.4. Conclusions
This NP system, PGA-PEG coated Gd2O2S:Eu, enables a 2nd generation
theranostic approach whereby the NP is not only able to deliver drug and image NP
location, but the interaction between NP and drug enables a metric for measuring the
amount of drug loaded within the NP. Characterization data confirms the presence of a
polymer coating comprised of 20 wt% PGA and 10 wt% PEG, and the Gd2O2S:Eu NP
radioluminescent properties are maintained after polymer coating. Moreover, spectral
overlap between the photosensitizer PpIX and the NP’s radioluminescence enables the
particle to measure drug loading in a dose sensitive manner. This phenomenon was
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observed both in water and through pork tissue using an X-ray excitation source and
spectrometer.

Moreover,

release

studies

showed

that

an

increase

in

XGP

radioluminescent intensity correlated with PpIX release. Thus, these particles are an
effective theranostic agent for imaging drug release. Imaging XGP following injection 1
cm deep in porcine liver tissue showed that radioluminescent imaging in deep tissue was
possible, a feat not possible using fluorescent quantum dots. While X-rays have excellent
soft tissue penetration that can excite the radioluminescent NP, QD are limited by the
poor tissue penetration of short, UV or visible light excitation wavelengths. Moreover,
non-invasive radioluminescent imaging of Gd2O2S:Eu-PGA-PEG NP in athymic nude
Balb/c mice with U-138 glioblastoma xenografts showed strong passive accumulation of
NP in intracranial tumors. Finally, coated and uncoated NP were shown to be non-toxic
in vitro in U-138 glioblastoma cells at a concentration up to 25 µg/ml. There were no
significant differences in toxicity between the two formulations at any concentration.
XGP showed no significant systemic toxicity at concentrations up to 75 mg/kg when
administered to Balb/c mice via tail vein injection. Thus this nanoparticle system is a
versatile, theranostic tool for imaging drug delivery.
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CHAPTER FIVE
CONCLUSIONS
Nanotechnology can enhance current cancer therapies by improving the delivery
of drug to tumors over biological barriers, prolonging drug resistance in the body, and
providing tools to measure the delivery of drugs in situ. While nanotechnologies can
improve the clinical efficacy of drugs, the growing field of theranostic nanomedicine has
yet to deliver a comprehensive platform capable of mediating both controlled drug
delivery while also quantitatively measuring drug loading and release. Theranostic
nanomedicine aims to merge both controlled drug delivery and imaging, and hybrid
organic-inorganic nanoparticles offer a potentially robust platform that capitalizes on the
optimal imaging properties of inorganic nanoparticles and the controlled delivery
properties of polymeric materials. Moreover, polymeric coatings on inorganic
nanoparticles may also improve their utility for biomedical applications by mitigating
potentially toxic side effects. Challenges in development of a theranostic nanoparticle
system include toxicity concerns surrounding nanomaterials and physical limitations for
imaging. The presented work demonstrates an approach that may be utilized to
functionalize inorganic nanoparticles that can be translated across multiple nanoparticle
“templates,” and the data also points to the use of these particles to measure drug
concentrations in situ. Moreover, the polymer-functionalized nanoparticles were able to
mitigate nanomaterial toxicity, control delivery of anticancer drugs, and non-invasively
measure the concentration of drug loaded in the nanoparticle.
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Figure 5.1 One-pot, room temperature synthesis approach enables interchangeable use of
inorganic NP for functionalization with biodegradable polymers.
5.1. Polymer Coatings Improve Nanoparticle Toxicity Profile
Nanoparticles, in particular inorganic NP, face concerns regarding toxicity
mediated by NP aggregation, increased cellular oxidative stress, and toxicity due to
nanoparticle interaction on a cellular and sub-cellular level. We developed a one-pot,
room temperature approach to coat inorganic NP with the FDA-approved polymers
poly(lactide) (PLA), poly(glycolide) (PGA), and poly(ethylene glycol) (PEG). We
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hypothesized that the polymeric coating would mitigate inorganic NP toxicity, enable
drug encapsulation, and prolong drug release. The rationale being that the multifunctional
polymer coating would mediate the interaction between NP and cell through the less
toxic polymer layer, sequester and control the release of hydrophobic drug within the
polymeric core (PGA or PLA), and improve the aqueous dispersion of NP via the PEG
outer layer. This functionalization approach could be applied across hydroxylfunctionalized carbon nanotubes (CNT-OH), hydroxyl-functionalized nano-graphene
(Gr-OH),

and

amine-functionalized

europium-doped

gadoliniumsulfoxide

radioluminescent nanoparticles (Gd2O2S:Eu-NH2). Proof-of-concept work with PLAPEG coated CNT (CLP), showed that the hydrophobic anticancer drug paclitaxel (PTX)
could be sequestered within the hydrophobic PLA coating. PLA mediated the release of
PTX over a one-week period, and CLP loaded with PTX was shown to be more effective
than free PTX when treating U-87 glioblastoma in vitro.
Furthermore, the PLA-PEG coating on CNT significantly improved CNT toxicity
profile. In vitro studies with U-87 glioblastoma and human umbilical vein endothelial
cells (HUVEC) showed that CLP was significantly less toxic compared to pristine CNT.
In vivo maximum tolerated dose studies in Balb/c mice showed that the PLA-PEG
coating on CNT doubled the maximum tolerated dose from 25 mg/kg (for CNT) to 50
mg/kg. Thus, coating inorganic nanoparticles in FDA-approved polymer not only
increased their functionality as a drug delivery vehicle, but also improved their safety for
use in a biomedical application.
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Figure 5.2 Coating inorganic NP with polymer decreases particle aggregation, and
mediates the interaction of inorganic NP with cells.
5.2. Controlling Drug Delivery
A number of factors influence drug loading and release kinetics from
nanoparticles including polymer thickness, nanoparticle size, drug chemistry, polymer
degradation rates, and polymer chemistry. Multilayered particles have been shown
improve control over drug release kinetics. We hypothesized that by extending the onepot reaction approach to sequentially coat NP with multiple polymer layers (e.g. PLAPGA-PEG, PGA-PLA-PEG, PLGA-PEG) it would be possible to control drug release
kinetics.
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Figure 5.31 Multilayered polymer coatings enable higher degree of control of drug
release kinetics.
The rationale being that by controlling the polymerization conditions it would be possible
to control polymer coating thickness, composition, enable multilayered particles, and in
turn control drug release characteristics. Results showed that by controlling the synthesis
conditions it was possible to tailor single polymer coating thickness, order of polymer
coatings, and relative polymer coating thickness in multilayered constructs. Using
dasatinib (DAS) as a model drug, we showed that multilayered polymer coatings were
able to closer approximate zero-order release kinetics compared to single layer and
random copolymer (PLGA) coatings. Furthermore, multilayered CNT were more
efficacious when treating U-87 glioblastoma in vitro compared to free DAS, and DAS
loaded into PLA-PEG NP (no CNT). The broader implications of this work are that the
multilayered coating may be applied across more inorganic NP platforms, enabling a
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higher degree of control over drug release characteristics. This therefore becomes a
highly controllable system for creating hybrid organic-inorganic drug delivery vehicles.

5.3. Measuring In Situ Drug Concentration
Applying the one-pot room temperature approach for NP functionalization, we
were able to coat radioluminescent Gd2O2S:Eu nanoparticles with PGA-PEG. These
nanoparticles are able to convert X-ray irradiation to visible light, emitting at 630 nm.
The benefit of radioluminescence over other optical approaches is the low
autofluorescence in radioluminescent imaging, and excellent soft tissue penetration of Xray radiation compared to ultraviolet (UV), visible (Vis), and near-infrared (NIR)
wavelengths. Moreover, the PGA-PEG coating encapsulated the hydrophobic
photosensitizing drug protoporphyrin IX (PpIX). The photoluminescent emission
spectrum of Gd2O2S:Eu overlapped with the absorption spectrum of PpIX, and the drug
could therefore be used to attenuate the luminescent intensity of the NP in a dosedependent manner. We hypothesized that this NP could be used to measure drug
concentrations in situ due to the overlap of spectral characteristics. Indeed, the
attenuation of NP radioluminescence was directly correlated to loaded drug
concentration. This phenomenon was observed both in water and through pork tissue,
indicating that the radioluminescent NP was sensitive enough to report drug loading
concentrations in deep tissue.
As an imaging agent, the PGA-PEG coated Gd2O2S:Eu NP (XGP) was
significantly better than other imaging nanoparticles, such as quantum dots (QD). QD are
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excited in the UV/Vis range of light, a range that is strongly attenuated and scattered by
hemoglobin in blood and tissue. Thus, QD were used as a control and radioluminescent
imaging showed that XGP was easily discernible when injected 1 cm deep in blood-rich
porcine liver tissue, while QD were not visible under fluorescent imaging. This is
possibly due to the attenuation of excitation wavelengths for QD, whereas X-ray can
easily penetrate the porcine liver. Furthermore, the capacity for XGP to act as an imaging
agent was demonstrated with intracranial U-138 glioblastoma xenograft models in
athymic nude Balb/c mice. NP were administered through a tail vein injection, and
noninvasive radioluminescent imaging of mice after 24 hr showed appreciable
luminescent signal from the brain (i.e. the intracranial tumor).
Toxicity studies of XGP in U-138 glioblastoma in vitro, and in maximum
tolerated dose studies in Balb/c mice showed that XGP was relatively non-toxic. In vitro
there was no significant toxicity at 25 µg/ml, and no significant toxicity between
uncoated Gd2O2S:Eu and XGP at any dose. In vivo, XGP showed no systemic toxicity at
concentrations up to 75 mg/kg. Thus, this system offers a potential theranostic NP
capable of measuring in situ drug concentrations and imaging NP biodistribution noninvasively.

5.4. Limitations
While the research presented represents steps towards the development of a
quantitative theranostic nanomedicine, there are still practical challenges towards
realizing a nanotechnology capable of in situ measurement of drug release kinetics.
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Figure 5.2 Radioluminescent NP enabled measuring drug release kinetics due to drug
quenching NP radioluminescent signal. As drug releases, signal strength returns.
One of the primary challenges this type of theranostic nanomedicine, one that utilizes the
overlap of optical properties of nanoparticle and drug for measuring drug release kinetics,
is the dependence on drugs that have distinct and strong optical properties. This research
was able to show that release kinetics could be measured using protoporphyrin IX as a
model drug, and the literature frequently uses doxorubicin and ibuprofen. However, such
a system is not suitable for drugs that do not have strong optical absorbances in the
optical transmission window of 650-950 nm. Moreover, the use of optical phenomena is
suitable for imaging and quantifying drug release with superficial tumors, or tumors that
are within the penetration depth of visible light. However, some tumors may have
difficulty imaging through dense bone tissue, such as intracranial tumors.
Concerns also exist regarding the long-term fate of inorganic NP. Our data shows
that polymer coatings can mitigate toxicity associate with inorganic NP in vitro and in
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vivo. However, the long-term fate of such nanomaterials is unknown, and systematic
studies of NP toxicity are relatively recent in the literature. Thus, such a theranostic
nanomedicine must present robust evidence supporting its clinical use. Some
nanomaterials, such as gold nanoparticles and iron oxide, are already on the market and
have a history of clinical success. However new nanomaterials, such as the Gd2O2S:Eu
NP or CNT, must be investigated for their long term biodistribution, clearance, and
toxicity.

5.5. Summary
The presented results highlight the development of a theranostic NP system
capable of measuring drug concentrations and noninvasively imaging in deep tissue. The
results further demonstrate an approach that can improve the utility of inorganic NP for
biomedical applications by via a multifunctional polymeric coating. The approach for NP
functionalization can be applied across a number of NP platforms, and multifunctional
coatings serve to improve the biocompatibility of nanomaterials and mediate controlled
drug release. The combination of radioluminescent nanoparticle with the polymeric
coating represents a small step towards more functional theranostic agents that can not
only combine delivery and imaging, but also measure the concentration of drug noninvasively. Furthermore, the development of hybrid NP may lead to innovative
approaches to the diagnosis and treatment of cancer.
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CHAPTER SIX
RECOMMENDATIONS
Based on the current state of the relevant literature, the data presented, and the
limits of these studies, the following future work is recommended:

1. In vivo tumor reduction models
Previous studies have shown the improved safety of carbon nanotubes (CNT) following
coating with PLA-PEG both in vitro and in vivo. Furthermore, the multifunctional
polymer coating enabled controlled release of paclitaxel (PTX) and dasatinib (DAS),
which improved therapeutic efficacy in vitro compared to free drug and spherical PLAPEG NP. It would be interesting to see how CNT-PLA-PEG would improve the
therapeutic efficacy in a more complex biological setting, i.e. an in vivo tumor xenograft
volume reduction study. Previous data (Appendix I) has shown that CNT-PLA-PEG is
able to accumulate when administered intravenously in intracranial U-138 glioblastoma
xenografts in athymic nude Balb/c mice. However, observing the therapeutic efficacy of
drug-loaded CNT-PLA-PEG compared to free drug or spherical PLA-PEG NP would
provide further insight into the potential benefits of this drug delivery vehicle.

2. Coat different shaped NP
Shape has been shown to play a critical role in the cellular uptake, biodistribution, tumor
accumulation, and circulation time in nanomedicine [1-6]. It would be interesting to coat
multifunctional polymers on different shaped NP and study their release kinetics, cellular
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uptake, biodistribution, and efficacy in vitro and in vivo to deliver drugs. Preliminary
data with plate-shaped, PLA-PEG coated nano-graphene (Appendix I) shows distinct
differences between the plate shaped NP, and PLA-PEG coated CNT, which have a more
fibrillar shape. It would be interesting to see how different, possibly biomimetic shaped
NP may change the utility of polymer coated NP.

3. Expand coating to other polymers
A number of other polymers may be used for ring opening polymerization. This coating
method could be attempted, optimized, and refined with different monomers such as εcaprolactone [5] or p-dioxanone [7, 8]. For example, ε-caprolactone was shown to
successfully polymerize poly(caprolactone) (PCL) on hydroxyl-functionalized CNT.
However, we had limited success repeating this study. It would be interesting to see if
changing

reaction

conditions

(e.g.

reaction

time,

monomer/catalyst

ratio,

monomer/initiator ratio, temperature, solvent system, etc.) could produce better yield.
Incorporating new polymers into the multilayered constructs could also prove interesting
towards modifying loading and release kinetics of drugs [9, 10].

4. Expand the number of drugs used
Currently we investigated two drugs: PTX and DAS [5, 11, 12]. However, there are many
drugs in pre-clinical development, clinical trials, or in clinical use that could benefit from
loading into a controlled release delivery vehicle. It would be interesting to investigate
the delivery of different drugs, or drugs delivered in combination from multilayered NP.
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For example, PTX is a mitotic inhibitor [13], and DAS works via the inhibition of the
BCR/Abl and Src family of tyrosine kinases [14]. However the loading efficiency, release
kinetics, and therapeutic efficacy of drugs that have a different mode of action or
different molecular targets could improve therapeutic efficacy when delivered via the
polymer coated drug delivery vehicle. Lapatinib is one such drug that inhibits the tyrosine
kinases HER2/neu and epidermal growth factor receptor [15], and methotrexate (MTX) is
another hydrophobic anticancer drug that works by inhibiting the enzyme dihydrofolate
reductase [16]. Thus, all four of the drugs mentioned here have different modes of action,
and varying drugs may lead to improved efficacy to treat different cancers. Furthermore,
therapeutic efficacy of new agents could benefit from administration via a controlled
release delivery vehicle [17, 18].

5. Study polymer functionalized upconversion nanoparticles as theranostic agents.
Upconversion NP, particles capable of converting near infrared (NIR) light into visible
light, have been previously used as mediators of photodynamic therapy and as imaging
agents [19-21]. While radioluminescent NP have better soft tissue penetration,
upconversion NP have other advantages such as no toxicity associated with high-energy
radiation. Moreover, NIR light still has decent tissue penetration (3.5 cm), low
autofluorescence, and tissue can be exposed to NIR radiation at higher intensities for
longer. It would be interesting to study polymer coated upconversion particles for
measuring drug concentrations and release, and as mediators to activate photosensitive
drugs.
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6. Radioluminescent nanoparticles for photodynamic therapy.
Our data shows that radioluminescent NP could measure drug release kinetics. However,
it would be interesting to study whether radioluminescent NP could mediate
photodynamic therapy. Photosensitizers face several clinical limitations. First, systemic
distribution of drug can result in accumulation and photosensitivity in non-target tissues
and organs, such as the skin and eyes [22]. Secondly, activation of PS by visible light is
limited by the attenuation and scattering of activation wavelengths of light. Therefore
PDT is generally reserved for pathologies that are easily accessible to a light source such
as melanoma or head and neck cancer. NPs offer solutions to these challenges by
sequestering photosensitizers into a vector that improves their biodistribution and
pharmacokinetic properties. Moreover, NPs that convert radiation wavelengths that more
easily penetrate tissue (i.e. X-ray or NIR) into visible light may enable deep tissue
activation of PS. Thus, utilizing the emission wavelength of radioluminescent NP to
activate PS would enable treatment of tumors in deep tissue.

7. Study the long term fate and effects of inorganic NP
While in vitro dose escalation and in vivo maximum tolerated dose studies elucidated a
safe range of use for polymer coated NP, it would be prudent to study the long term fate
and effects of these NP following systemic administration in vivo. In particular, the work
and data presented regarding the radioluminescent Gd2O2S:Eu-PGA-PEG (XGP) NP
indicate safe ranges to avoid acute toxicity, however NP that remain for prolonged
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periods in the body may begin to exhibit systemic toxicity due to NP degradation and
leaching of constituent components (e.g. europium) [23, 24].

8. Expansions of NP systems to broader applications
It would be interesting to apply these inorganic-organic hybrid NP to applications beyond
cancer therapy either in drug delivery, or potentially tissue engineering scaffolds. Many
scaffolds in literature are comprised of a polymer matrix with some inorganic component
embedded, particularly for bone regeneration [25-27]. The inorganic component may
provide mechanical support, act as a sensor, or promote biological cues. For example,
Mattioli-Belmonte et al. [26] showed that for PCL scaffolds loaded with CNT, varying
the design of CNT the percent CNT loading significantly influenced mechanical
properties, cell behavior of MG-63 human osteoblast-like cells, and cell viability.
Covalently modifying the CNT with polymer, as opposed to merely encapsulating CNT
within a polymer matrix, may mitigate CNT-induced toxicity or alter the interaction of
cells with the scaffold. Thus, incorporation inorganic NP into polymeric scaffolds where
the polymer is covalently attached to the inorganic component may show interesting
applications for scaffolds or other biomedical applications.
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